The QualityStocks Daily Friday, January 22nd, 2021

Today's Top 3 Investment Newsletters

Tip.us(SING) +255.56%

QualityStocks(EWLL) +100.00%

Schaeffer's(GME) +51.08%

The QualityStocks Daily Stock List

9 Meters Biopharma, Inc. (NMTR)

Zacks, Stocktwits, BioPharmCatalyst, The Globe and Mail, Investing.com, Nasdaq, Finviz, Simply Wall St, DBT News, Stockopedia, Morningstar, Webull, Invest Million, MarketBeat, MarketWatch, Market Screener, Fintel, Stock Analysis, Finbox, Stockhouse, Invest Chronicle, ChartMill, YCharts, The Street, docoh, GuruFocus, Barron’s, Fintel, and Seeking Alpha reported earlier on 9 Meters Biopharma, Inc. (NMTR), and today we report on the Company, here at the QualityStocks Daily Newsletter.

9 Meters Biopharma, Inc. is a clinical-stage rare and unmet needs-focused gastroenterology company. It is advancing NM-002, a proprietary long-acting GLP-1 agonist into a Phase 2 trial for Short Bowel Syndrome (SBS), a rare, orphan disease. In addition, the Company is advancing larazotide, a Phase 3 tight junction regulator undergoing evaluation for patient-reported symptom improvement in non-responsive celiac disease. 9 Meters Biopharma is based in Raleigh, North Carolina. The Company lists on the NasdaqGS.

A strong Management Team with a history of bringing novel therapeutics to market leads 9 Meters Biopharma. The Company owns all worldwide rights to its products. These products are backed by more than 150 patents worldwide.

9 Meters Biopharma is also developing NM-003: a long-acting GLP-2 agonist. It is being developed for an undisclosed rare GI indication. Furthermore, it is developing NM-004: a small molecule. It is being developed for an undisclosed rare GI indication as well.

This past December, 9 Meters Biopharma announced a collaboration with the European Biomedical Research Institute of Salerno (EBRIS), to advance to a study in order to evaluate the safety and tolerability of larazotide when delivered to lung tissue in healthy volunteers. Larazotide, a first-in-class tight junction modulator, is hypothesized to act on lung endothelial cells. EBRIS and 9 Meters Biopharma have entered into a material transfer agreement for drug supply sufficient to start and complete a Phase 1 study in Australia this year to assess the safety and tolerability of larazotide when delivered directly to the lungs.

EBRIS will manage the operations and financing of this study. EBRIS) is a non-profit foundation and research collaboration based in Salerno, Italy. It has partner institutions that include the University of Salerno, Italy, and the Massachusetts General Hospital for Children in Boston, Massachusetts. The foundation incorporates a broad network of relationships within the global scientific community including companies in the pharmaceutical and agri-food sector.

9 Meters Biopharma, Inc. (NMTR), closed Friday’s trading session at $1.25, up 1.626%, on 5,328,289 volume with 8,082 trades. The average volume for the last 3 months is 7,630,682 and the stock's 52-week low/high is $0.370099991/$1.76999998.

Gold Springs Resource Corp. (GRCAF)

Newsfilecorp, GlobeNewswire, InvestingNote, Dividend Investor, Wallet Investor, Gold Stock Data, Cambridge House, Simply Wall St, Stockwatch, OTC Markets, Capital Ideas Media, Mining Stock Education, Nasdaq, TradingView, SmallCapPower, CRWEWorld, Fintel, TMXmoney, MarketWatch, Investors Hangout, StockCharts, Dividend.com, InvestorsHub, Proactive Investors, Nasdaq, TradingView, Big News Network, and Stockhouse reported earlier on Gold Springs Resource Corp. (GRCAF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Gold Springs Resource Corp. is a gold exploration company creating value through the exploration and development of the PEA-stage Gold Springs Project in Nevada and Utah. Its Management has wide-ranging experience in international exploration and the mining industry. The Company previously went by the name TriMetals Mining, Inc. It changed its name to Gold Springs Resource Corp. in November of 2019. Incorporated in 2006, Gold Springs Resource is headquartered in Vancouver, British Columbia.

Ownership of the Gold Springs Project is 100 percent Gold Springs Resource Corp. The Gold Springs Project is in the prolific Great Basin of the Western United States, in one of the best mining jurisdictions globally. The Company believes that the Gold Springs Project has the potential to host multimillion-ounce gold and silver resources.

The Gold Springs Project includes several historical mining districts. These include the Deer Lodge, Fay, and the Eagle Valley districts, all within Nevada, and the Gold Springs District in Utah. Gold Springs is an advanced exploration stage gold project. It bestrides eastern Lincoln County, Nevada, and western Iron County, Utah – the abovementioned Great Basin of the Western United States.

This Project has many targets with four resource zones (North Jumbo, South Jumbo, Grey Eagle, and Thor) open for expansion. The Gold Springs Project covers roughly 7,847 hectares, consisting of Federal lode claims, Utah State leases, and patented mining claims held through leases and purchases.

The priority targets are to extend the North Jumbo and South Jumbo towards each other along a 5.5-kilometer Jumbo Trend. The Project has shallow open pit, low sulphidation, heap leach potential. Regarding the Project’s outlook, it is a district-scale property with medium-term potential with drilling for resource upgrade and expansion at the Jumbo Trend and for identification of high-grade mineralization at the new Homestake Target.

Last month, Gold Springs Resource reported high-grade rock chip sampling results from the West Pinyon target and provided an introduction to the buried North Jennie target. West Pinyon is situated within the Company's Nevada portion of the claim block; North Jennie straddles the State line between Nevada and Utah.

West Pinyon target produced rock chip sampling results as high as 42.30 g/t Au and 131.0 g/t Ag from banded epithermal quartz vein material. The North Jennie target represents a significant CSAMT geophysical anomaly defined by the recently completed GRC survey (Press Release September 2, 2020). Only one hole has been drilled in the North Jennie target intersecting gold values as high as 4.6 g/t. The Company stated that results from its work program highlight the quality of these targets as they are readied for future drill programs.

Gold Springs Resource Corp. (GRCAF), closed Friday’s trading session at $0.09205, up 5.5619%, on 2,500 volume with 1 trade. The average volume for the last 3 months is 26,977 and the stock's 52-week low/high is $0.049600001/$0.124750003.

NetSol Technologies, Inc. (NTWK)

Zacks, Smarter Analyst, Investor Place, Invest Million, Whale Wisdom, GuruFocus, Simply Wall St, MacroTrends, Invest Chronicle, Invest.com, last10k, Fintel, MarketWatch, MarketBeat, Nasdaq, Proactive Investors, Business Insider, Seeking Alpha, Stocktwits, Stocknews, Newsheater, Wallet Investor, DBT News, Stockhouse, GlobeNewswire, Finbox, CSI Market, Finviz, TMX.com, CEO.ca, Market Screener, YCharts, Morningstar, and TradingView reported previously on NetSol Technologies, Inc. (NTWK), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

NetSol Technologies, Inc. is a global business services and enterprise application solutions provider. The Company is an international provider of IT (Information Technology) and enterprise software solutions primarily serving the worldwide leasing and finance industry. It has been serving the world’s top asset finance & leasing companies with smart software technology for more than 40 years. NasdaqGS-listed, NetSol Technologies is based in Calabasas, California.

The Company’s set of applications is backed by 40 years of domain expertise. It is supported by a dedicated team of more than 1300 professionals placed in eight strategically located support and delivery centers around the world. NFS, LeasePak, LeaseSoft or NFS Ascent® – help companies transform their Finance and Leasing operations, providing a totally automated asset-based finance solution covering the complete finance and leasing lifecycle.

NFS Ascent is built on pioneering, modern technology. It enables auto, equipment, and big ticket finance companies to run their retail and wholesale finance business easier. NFS Digital is a combination of the Company’s core strengths, domain, and also technology. It is curated digital touchpoints for a client’s teams, partners, and customers.

Last month, NetSol Technologies announced that it signed an agreement with an international automotive financial services company in China to upgrade from the Company’s legacy NFS system to its premier, next-generation Ascent® platform. The multi-year, multi-million-dollar agreement includes licensing, support and services revenues components, which will be recognized respectively over the life of the contract. NetSol’s NFS Ascent® platform was selected for its first-rate capabilities and proven track record for success both in Asia-Pacific (APAC) and across the globe.

Also in December, NetSol Technologies announced that it appointed Co-Founder, President of Global Sales and CEO of Otoz Naeem Ghauri, to serve as President of NetSol Technologies, Inc., effective immediately. The newly created role will oversee Company operations domestically and internationally with reporting duties directly to the Chairman and CEO. As President of NetSol, Ghauri will be responsible for P&L for all subsidiaries and also developing a cohesive strategy to market NetSol’s core business and new, innovative solutions.

NetSol Technologies, Inc. (NTWK), closed Friday’s trading session at $4.07, off by 3.5545%, on 72,036 volume with 411 trades. The average volume for the last 3 months is 71,446 and the stock's 52-week low/high is $2.00/$4.57999992.

Greene Concepts, Inc. (INKW)

Guerilla Stock Trading, Fintel, Investors Hangout, Pink Investing, Stock Reads, Pennystocks.news, All Cap Research, OTC PR Wire, WeTradeHQ, TradingView, Nasdaq, Financial Buzz, GuruFocus, EIN Presswire, InvestorsHub, Dividend Investor, News Break, StockInvest.us, OTC Markets, OTC Dynamics, Street Insider, Market Screener, Investor Ideas, FX Empire, Stockhouse, Stockopedia, CEO.ca, Seeking Alpha, Newsfilecorp, Morningstar, Wallet Investor, GlobeNewswire, Stockwatch, and Business Insider reported beforehand on Greene Concepts, Inc. (INKW), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Greene Concepts, Inc. is an emerging leader in the global scientifically formulated beverage industry. Through its earlier acquired wholly-owned subsidiary, Mammoth Ventures, Inc., it has entered into the specialty beverage and bottling business. Greene Concepts has completed the 100 percent acquisition of Mammoth Ventures. Greene Concepts has its BE WATER™ brand. The Company is based in Clovis, California and lists on the OTC Markets.

Mammoth Ventures is a holding company that includes the 60,000 sq. ft. beverage and bottling facility located just outside of Asheville, North Carolina. Furthermore, the acquisition of the holding company includes the building, all bottling equipment, fixtures, inventory, and any and all other assets held and owned by Mammoth Ventures, Inc.

This facility will focus on a variety of beverage product lines. These include, but are not limited to, CBD (cannabidiol) infused beverages, spring and artesian water, and enhanced athletic drinks in addition to other product offerings.

Additionally, through its subsidiary, Water Club, Inc., it intends to pursue subscription-based delivery of water and scientifically formulated beverages directly to the consumers home, and market the convenience of this service via social media affiliate marketing partners.

Greene Concepts has a new marketing and distribution focus in the lucrative Southeast Asia bottled water market. Along with domestic market growth, the Company plans for expansion into the fast growing Southeast Asia market. This includes Singapore, Indonesia, Thailand, Malaysia, and Vietnam.

Greene Concepts signed a property purchase agreement for an additional 10 acres of land adjacent to its Marion, North Carolina bottling facility. This additional acreage will provide it with the ownership of seven wells and unlimited access to the underground pristine water aquifer that lays deep beneath the property situated within the Pisgah National forest.

Greene Concepts plans to offer its vast water supply for industrial, government, and also local use around the North Carolina area and beyond. It owns the land housing seven Spring and Artesian wells. Therefore, the Company’s focus is to expand the use of its unlimited water supply to produce considerable sales beyond just bottled water manufacturing. It states that this affords many ways for Greene Concepts to supply limitless amounts of fresh water to multiple markets without additional manufacturing costs.

Mr. Lenny Greene, Chief Executive Officer of Greene Concepts, stated, "We are elated to present a revolutionary way to serve our local and surrounding communities. Our bottling plant is now ready to produce massive sales beyond just bottled water production. Besides producing an unlimited amount of bottled water, well beyond the previously announced 192 million bottle production count, we can now properly utilize our unlimited water supply for industrial, government and local economic use…”

Greene Concepts, Inc. (INKW), closed Friday’s trading session at $0.0037, up 78.4853%, on 388,939,198 volume with 1,949 trades. The average volume for the last 3 months is 32,934,877 and the stock's 52-week low/high is $0.000099999/$0.005499999.

Target Group, Inc. (CBDY)

TipRanks, BioSpace, Emerging Growth, Market Exclusive, Stock Day Media, Stockhouse, PR Newswire, InvestorsHub, Stock Market MBA, MarketWatch, Investing.com, OTC.Watch, Investor Ideas, GuruFocus, Wallet Investor, Nasdaq, OTC Markets, EIN Presswire, YCharts, Simply Wall St, GlobeNewswire, Morningstar, Barchart, last10k, Equities, CSI Market, TradingView, Corporate Information, Investors Hangout, Dividend.com, and Dividend Investor reported earlier on Target Group, Inc. (CBDY), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Target Group, Inc. engages in the medicinal and recreational cannabis business in Canada and in the United States in those States where cannabis has been legalized for medicinal and recreational use. The Company is curating ultra premium cannabis brands. Target Group is a seed to sale cannabis and hemp CPG (Consumer Packaged Goods) company.

Target Group is expanding its operations, building a worldwide network of manufacturing, distribution, production, and sales operations. The Company has its head office in Vaughan, Ontario. Its shares trade on the OTC Market Group’s OTCQB.

Target Group is curating an exclusive portfolio of quality cannabis brands through selective partnerships and strategic acquisitions, spreading risk across growth opportunities. The Company’s subsidiary, Canary Rx, Inc., is a Licensed Producer under the Cannabis Act. Canary will produce premium, small-batch cannabis, grown organically in soil. Its 44,000 sq. ft. custom-engineered facility is in Norfolk County, Ontario, with room to grow.

Target Group’s partners include Canary, wisp (wellness your way), Serious Seeds, Can ABC Services, True Focus, and Cannavolve. The Company utilizes vertical integration to optimize quality, reliability, and efficiency across the entire seed-to-sale value chain. Target continues to expand its national and international presence through structuring production, manufacturing, and sales infrastructure worldwide. It leverages product diversification, innovation, as well as operational expertise to solidify long-term growth and stability.

Target Group announced in October of 2019 that its wholly-owned subsidiary, Canary RX, was granted licenses to cultivate, process and sell cannabis pursuant to the Cannabis Act (Bill C-45). Strategically located just outside of Toronto, Ontario, Canary RX is cultivating cannabis in its 44,000 square foot facility, producing 3600 kilograms per year.

More recently, Target Group announced that its wholly-owned subsidiary, Canary RX, entered into an agreement to form a Joint Venture Partnership (JV) with Thrive Cannabis, Inc. in Norfolk County, Ontario for the production of premium craft cannabis. The terms of the 5 year definitive agreement have Target and Thrive each with a 50 percent ownership of the JV.

Target, through Canary RX, will permit Thrive Cannabis to produce premium craft grown cannabis in 7 of its 8, 2300 square foot growing rooms within its existing 44,000 sq. ft. licenced cultivation facility in Norfolk County. Thrive will also maintain and supervise the staff on their proprietary methods of cultivation that it presently utilizes from its production in Canada. The expectation is that operations within the facility will commence immediately.

Target Group, Inc. (CBDY), closed Friday’s trading session at $0.037, up 97.0706%, on 4,841,597 volume with 153 trades. The average volume for the last 3 months is 417,138 and the stock's 52-week low/high is $0.006/$0.037999998.

STWC Holdings, Inc. (STWC)

CannabisFN, StocksBeat, All Stocks Today, Street Insider, PotNetwork, Cannabis Dispensary, OTC Markets, Cannabis Business Times, Invest Tribune, Stock Target Advisor, Real Investment Advice, OTC.Watch, InvestorsHub, Simply Wall St, Stockhouse, 4-Traders, and Seeking Alpha reported earlier on STWC Holdings, Inc. (STWC), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

STWC Holdings, Inc. is a foremost cannabis consultant and industry pioneer listed on the OTC Markets Group’s OTCQB. It offers a wide-ranging ecosystem of entities and services, which support the expanding cannabis industry. Established in 2012, the Company was previously known as Strainwise, Inc. It changed its name to STWC Holdings, Inc. in June of 2016. STWC has its corporate office in Lakewood, Colorado.

The Company offers capital, strategic partnership, and seed-to-sale consulting. It also offers design, marketing and advertising services. STWC provides its partners access to its complete suite of assets. It develops made-to-order solutions to address the range of challenges that cannabis entrepreneurs and businesses face.

SquareOne™ is the Company’s 3-phase consulting platform. It assists cannabis entrepreneurs in launching their new businesses successfully - with measurable results. With SquareOne™, STWC is able to deliver concise consulting services to cannabis entrepreneurs. The SquareOne™ consulting platform guides clients in understanding the financial dimensions and market conditions in their respective jurisdictions.

This past April, STWC Holdings announced that it executed a joint venture (JV) for the development of an innovative software package customized for the cannabis industry. The agreement with Dana Ress of Denver’s RedPoint Solutions will result in a software solution named Supergrower, targeted for July, which will address the complexities of conducting business in the arena of legal marijuana, with functionality across all four cannabis verticals: cultivation, manufacturing, distribution and retail.

STWC Holdings Chief Executive Officer, Erin Phillips, said, “After working with hundreds of operators in the cannabis industry, we realized that most operators are looking for powerful tools to manage their day-to-day operations and plan for the future. As cannabis businesses continue to evolve and mature, this issue will become increasingly insurmountable. Supergrower will provide the business analytics necessary for an operator to thrive in today’s cannabis industry.”

Under the JV, STWC Holdings and Ress will work together to develop an efficient and scalable software platform. It will be the first complete management system for the cannabis industry. The design of the Supergrower platform, an SaaS product, is to operate across all standalone software, aggregating data, performing analytics, and providing valuable insights to customers through customizable reports and dashboards.

STWC Holdings, Inc. (STWC), closed Friday’s trading session at $0.0039, up 50.00%, on 61,582,516 volume with 335 trades. The average volume for the last 3 months is 23,656,469 and the stock's 52-week low/high is $0.000099999/$0.014.

iLOOKABOUT Corp. (ILATF)

Penny Stock Hub, Stockwatch, HotOTCStocks, GlobeNewswire, Otc.watch, OTC Markets, MarketWatch, and Stockhouse reported earlier on iLOOKABOUT Corp. (ILATF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, iLOOKABOUT Corp. is a software, data analytics, data aggregation, and visual intelligence company focused on real property. The Company provides powerful data analytics to the real estate industry via its Real Property Tax Analytics software offering. iLOOKABOUT mainly serves the property assessment, property taxation, municipal, insurance, and appraisal sectors, public and private, in North America. The Company has offices in London, Ontario and Toronto, Ontario.

iLOOKABOUT’s proprietary StreetScape imagery and real property focused web-based application, GeoViewPort, unifies property related data and enables desktop review of properties. The Company has integrated analytics and workflow management applications into GeoViewPort that create highly valued service offerings for its clients. To augment its technology-based offerings, iLOOKABOUT provides real estate consulting services, with an emphasis on the Property Tax and Valuation sectors.

Regarding Tax Analytics, RPTA (Real Property Tax Analytics) is a Software-as-a-Service (SaaS) application. It combines the data attributes of over 5.5M properties in Ontario, integrating mapping, imagery, and census data with Municipal Property Assessment Corporation (MPAC) assessment data. Regarding Tax Consultancy Services, iLOOKABOUT’s Municipal Tax Advisory Group professional services include Assessment Base Management; Analytics Reports; Tailored Tax Policy Planning and Support; and Appeals Management.

iLOOKABOUT Corp. (ILATF), closed Friday’s trading session at $0.5317, up 50.1553%, on 959,210 volume with 222 trades. The average volume for the last 3 months is 19,583 and the stock's 52-week low/high is $0.064999997/$0.610000014.

Bespoke Extracts, Inc. (BSPK)

Simply Wall St, Stockopedia, InvestorsHub, Wallmine, Stockhouse, Ventureline, GuruFocus, Investors Hangout, Barchart, Wallet Investor, Infront Analytics, YCharts, Market Screener, Morningstar, Market Exclusive, Marketwired, Insider Financial, and MarketWatch reported earlier on Bespoke Extracts, Inc. (BSPK), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Bespoke Extracts, Inc. is a producer of high quality, flavorful, hemp-derived cannabidiol (CBD) extract products. The Company established in early 2017 to introduce a proprietary line of premium quality, all-natural CBD products in the form of tinctures and capsules for the nutraceutical and veterinary markets. Bespoke Extracts is headquartered in Sunny Isles Beach, Florida. The Company’s shares trade on the OTC Markets Group’s OTCQB.

The Company’s products are marketed as dietary supplements and distributed through the Company’s direct-to-consumers e-commerce store. Bespoke’s products are produced using pure, all natural, zero-THC phytocannabinoid-rich (PCR) hemp-derived CBD. CBD is non-psychoactive. CBD (cannabidiol) is one of over 85 cannabinoids found in cannabis. CBD is present in more significant quantities in hemp than it is marijuana.

Bespoke Extracts’ mission is to become one of the world’s most trusted sources for premium quality, all-natural, USA-grown, hemp-derived cannabidiol (CBD) products for the nutraceutical and veterinary markets. The Company strives to use only vegan, Fair Trade Certified, and organic ingredients with fast acting benefits for anyone looking for an alternative remedy. Bespoke’s farmers have been innovators in hemp agriculture, farming practices, agrotech, as well as production for generations. Bespoke’s hemp is stable, high in CBD, low in THC, and resistant to pathogens and pests.

The Company’s products include Sport Lemon Lime Tincture – THC Free 1500MG; CBD Manuka Honey Tincture; and CBD Bacon Flavored Pet Tincture. Moreover, products include CBD Softgel Capsules; CBD Pain Relief Cream; and CBD Isolate Powder.

Bespoke Extracts announced this past November that its Board of Directors appointed Niquana (Nikki) Noel as President and Chief Executive Officer (CEO), effective immediately. Serving Bespoke as its Operations Manager, Noel assumed day-to-day leadership of the Company and joined its Board of Directors. Noel has spent close to two decades working with privately-held and publicly-traded micro and small cap companies.

Bespoke Extracts, Inc. (BSPK), closed Friday’s trading session at $0.088, up 95.5556%, on 2,616,883 volume with 491 trades. The average volume for the last 3 months is 206,051 and the stock's 52-week low/high is $0.007499999/$0.101649999.

Beyond Commerce, Inc. (BYOC)

Zacks, OTC Markets, Penny Stock Tweets, Stockhouse, InvestorsHub, YCharts, Street Insider, Market Screener, Wallet Investor, Simply Wall St, Financial Content, MarketWatch, Investors Hangout, Barchart, The Street, Tip Ranks, 4-Traders, GuruFocus, Stockopedia, OTC.Watch, TradingView, Morningstar, Insider Financial, and Stockinvest reported earlier on Beyond Commerce, Inc. (BYOC), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Beyond Commerce, Inc. is a planned provider of B2B (Business to Business) internet marketing analytics, technologies, and related services. The Company’s planned objective is to develop, acquire, and deploy disruptive strategic software technology that will build on organic growth potential. Additionally, its planned goal is to exploit cross-selling opportunities. Beyond Commerce is based in Las Vegas, Nevada. The Company’s shares trade on the OTC Markets Group’s OTCQB.

The Company operates as a holding enterprise that focuses on “big data” companies in the global B2B Internet Marketing Analytics/Technology and Services space. Beyond Commerce plans to provide a cohesive digital product and services platform. This is to provide clients with a single point of contact for their big data, marketing and related sales initiatives. The Company’s emphasis is to develop, acquire, and also deploy disruptive strategic software technology and market-changing business models through acquisition or organic growth.

Beyond Commerce, Inc. (BYOC), closed Friday’s trading session at $0.0015, up 50.00%, on 239,027,284 volume with 473 trades. The average volume for the last 3 months is 36,287,533 and the stock's 52-week low/high is $0.00025/$0.005299999.

MMEX Resources Corp. (MMEX)

Discovery Stocks, HydroCarbonProcessing, Investors Hangout, MarketWatch, MicroCapDaily, Stockhouse, Business Wire, 4-Traders, InvestorsHub, Morningstar, OTC Markets, and Wallet Investor reported earlier on MMEX Resources Corp. (MMEX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

MMEX Resources Corp. focuses on the acquisition, development and financing of oil, gas, refining and infrastructure projects in Texas and South America. The Company established to engage in the exploration, extraction, refining and distribution of oil, gas, petroleum products and electric power. A development-stage company, MMEX Resources is headquartered in Fort Stockton, Texas.

MMEX’s main areas of interest include the acquisition and potential development of refining, oil & gas assets in Texas, and the acquisition of oil and gas properties in Peru. In addition, main areas of interest include crude, oil and product export opportunities in Latin America, and the development of terminals, storage, refining, oil & gas in Brazil.

The Company’s projects include the Pecos County Refinery Project, Fort Stockton, Texas. Phase 1 of this project is a 10,000 BPD Crude Distillation Unit. Phase 2 is a 100,000 BPD Large-Scale Refinery. The project is in Sulfur Junction, about 20 miles northeast of Fort Stockton. The project is strategically positioned close to oil production in West Texas, with storage capability.

MMEX Resources signed an off-take agreement with Pilot Thomas Logistics. The off-take agreement is for the sale of its diesel fuel production from Phase 1 of the MMEX refinery project in Pecos County. In November 2017, MMEX Resources broke ground on Phase 1 of the MMEX Refinery Project in Pecos County. The agreement provides for Pilot Thomas Logistics to obtain 100 percent of the diesel production from Phase 1, roughly 4,200 barrels per day, for markets in the Permian Basin area principally for use in drilling operations.

MMEX Resources intends to develop a solar power project to provide electric power to its planned 10,000 barrel-per-day (BPD) crude distillation unit and its full-scale crude oil refinery in Pecos County near Fort Stockton, Texas.

MMEX Resources Corp. (MMEX), closed Friday’s trading session at $0.0004, up 100.00%, on 1,530,593,196 volume with 769 trades. The average volume for the last 3 months is 158,092,531 and the stock's 52-week low/high is $0.000000999/$0.0005.

CurAegis Technologies, Inc. (CRGS)

Penny Stock Tweets, Dividend Investor, Insider Mole, Equity Clock, Market Screener, Morningstar, MarketWatch, 4-Traders, InvestorsHub, Stockwatch, Investor Place, Simply Wall St, Marketbeat, Capital Cube, YCharts, Stock Invest, Barchart, The Street, OTC Markets, Infront Analytics, Stockhouse, last10k, Wallet Investor, and TradingView reported earlier on CurAegis Technologies, Inc. (CRGS), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter. 

Technologies, Inc. develops and markets advanced technologies in the areas of power, safety, and wellness. The Company consists of two independent divisions. One is its CURA Division and the other is its Aegis Division.  CurAegis is now concentrating on commercialization strategies in diverse technologies. These include the CURA system, which includes the myCadian™ watch that measures degradation of alertness and sleep attributes; the Z-Coach e-learning education and training tool, and the Aegis hydraulic pump. OTCQB-listed, CurAegis Technologies is based in Rochester, New York.

  The CURA™ system and the myCadian™ watch enable the user and third parties to anticipate and prevent undesired or disastrous situations caused by the degradation of alertness. CurAegis completed its validation studies of the CURA System at the University of Colorado at Boulder and the University of Rochester Medical Center. The Company previously said that it can now state that it can predict a person’s fatigue level, at close to laboratory accuracy, in real-time.

The CURA System consists of hardware and software, which measures numerous metrics to establish that a person's ability to perform a task or job appears to be degrading. The CURA division is developing a proprietary technology and family of products designed to measure the reduction in a person’s alertness and to train persons on how to improve alertness levels. The CURA System gives a person accurate and relevant real-time information regarding their current and long-term sleep and fatigue health.

The Company’s Aegis hydraulic pump (Aegis Division) is an innovative hydraulic design. Its goal is to deliver better efficiencies in a package that is smaller and lighter than contemporary technologies.  Moreover, in 2015, the Z-Coach e-learning tool was acquired by CurAegis Technologies. The Z-Coach® Wellness Program is a robust, proven and proprietary online sleep training and education solution to address sleep issues and improve wellness.

In December, Mr. Richard A. Kaplan, Chief Executive Officer of CurAegis Technologies announced that Mr. Lance F. Drummond was appointed to the Company’s Board of Directors. At present, Mr. Drummond is a Board member of Federal Home Loan Mortgage Corporation (Freddie Mac). He has served on the Audit Committee and Nominations and Governance Committee since 2015. He is a Board member for United Community Bank, Inc. since 2018, where he serves on the Risk Committee, Nominating and Governance Committee and Compensation Committee.

CurAegis Technologies, Inc. (CRGS), closed Friday’s trading session at $0.0399, up 64.876%, on 156,912 volume with 18 trades. The average volume for the last 3 months is 64,290 and the stock's 52-week low/high is $0.011099999/$0.150000005.

DroneGuarder, Inc. (DRNG)

OTC Markets, Barchart, StreetRegister.com, Insider Financial, InvestorsHub, 4-Traders, and Emerging Growth.com reported on DroneGuarder, Inc. (DRNG), and today we report on the Company, here at the QualityStocks Daily Newsletter.

DroneGuarder, Inc.  centers on commercializing a drone enhanced home security system as a turnkey solution. The design of its DroneGuarder Mobile App  is to let users have peace of mind within arms length, whether they are in their home or not. Established in San Francisco in 2017,  DroneGuarder has its head office in London, England.

The Company’s solution is app-based. It includes a drone, infrared camera, and an Android mobile app component. Upon an alarm being triggered, the DroneGuarder™ will immediately take off from a wireless charging pad.

The DroneGuarder™ assists in protecting against intruders. Upon an intruder being detected on the sensor net,  one can have the drone fly to the event location. Once there,  one can use the built-in microphone to issue a harsh warning to scare away intruders. If that fails, the high-quality HD film captured of the intruder can be uploaded to the cloud and forwarded to law enforcement agencies.

A variety of DJI drones is available and compatible with the DroneGuarder system. The design of the drones is to respond to commands from a user’s smart phone, and its native remote. This enables one to give it basic orders from anywhere.

DroneGuarder uses Swellpro as its drone supplier. DroneGuarder’s intention is to work jointly to embed its scanning AI image recognition technology into Swellpro’s SD5 drone platform. This will enable the DG Rescue to autonomously grid search for victims in a search area and alert the rescue crews through GPS location and streaming video where the victims are. DroneGuarder will be jointly developing DG Intruder with Swellpro using all the same technology, however it will be app based.

This past January, DroneGuarder announced the launch of its DG App on Google Play. The Company is enhancing the functionality for login and flight control including autonomously and controlled security sweeps. DroneGuarder secured new funding, which enables the Company to fund DG Rescue and DG Intruder product developments through to commercial release.

DroneGuarder believes that once both of its products are launched it will sell 5,000 to 10,000 drone units in the first year. The Company has its channels to market already in place, using Swellpro’s reseller network.

DroneGuarder, Inc. (DRNG), closed Friday’s trading session at $0.0018, up 80.00%, on 434,843,724 volume with 1,073 trades. The average volume for the last 3 months is 60,796,718 and the stock's 52-week low/high is $0.000099999/$0.0023.

Foothills Exploration, Inc. (FTXP)

MarketWired, OTC Markets, and InvestorsHub reported on Foothills Exploration, Inc. (FTXP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Foothills Exploration, Inc., through its wholly-owned subsidiary, Foothills Petroleum, Inc. (a Nevada corporation), is an early stage independent oil and gas exploration and production company. It involves in the acquisition and development of oil and gas properties in the Rockies. The Company’s goal is to acquire dislocated and underdeveloped oil and gas assets and maximize those assets. Foothills Exploration is headquartered in Denver, Colorado.

The Company’s strategy is to build a balanced portfolio of E&P assets through concentrating on acquiring producing and developmental properties in the Rockies and focusing on the generation of high-impact oil and gas exploration projects. Foothills Exploration’s goal is to build a land bank of more than 200,000 acres of proven, probable, and prospective reserves.

Currently, Foothills Exploration holds 41,181 acres in the Greater Green River Basin in Wyoming. Its Springs Prospect consists of 38,120 contiguous acres. This is a multiple objective oil resource play in the Greater Green River Basin.

Moreover, the Company has a 35 percent Working Interest (WI) in the Ladysmith Anticline prospect. This prospect is in Fremont County, Wyoming. Ladysmith Anticline in entirety amounts to 3,061 acres. Its location is between the Great Divide/Greater Green River Basin and the Wind River Basin.

Foothills also has its PawPaw Project. The Pawpaw project is a 3-D seismic defined prospect. It covers 4,467 acres and is a direct analog to the highly productive Tensleep Formation “Enigma” Field positioned two miles south.

The Company also has its Ironwood Project. The Ironwood Project is a 6,115-acre up dip field extension play. The adjacent “Cotton Creek” Field produced about 67 million barrels of oil (MMBO) and 68 billion cubic feet of gas (BCFG), chiefly from the Phosphoria Formation.

Foothills Exploration announced in February 2017 that since acquiring Tiger Energy Partners International on December 30, 2016, Foothills has successfully reworked two wells in its Duck Creek project obtaining production from the Green River formation.

Regarding the Duck Creek Area – Natural Buttes Field, Foothills Exploration plans to re-enter two wells in September in the Duck Creek region situated in Uintah County, Utah, in the Natural Buttes field. The Duck Creek wells recently had a third-party engineering report completed. The Report calculated a total PV-10 value of $707,000 of Proved Developed Producing and Proved Developed Non-Producing reserves.

Concerning the Altamont- Bluebell and Brundage Canyon areas, a third-party reserve report was conducted on certain properties, which were acquired via the Tiger Energy Partners International acquisition. According to this Report, the properties have roughly 5.4 million barrels of Proved Undeveloped Reserves. The well depths range from 5,500 feet in the Brundage Canyon area to roughly 18,000 feet in the Altamont-Bluebell area.

Foothills Exploration, Inc. (FTXP), closed Friday’s trading session at $0.001, up 66.6667%, on 157,728,888 volume with 156 trades. The average volume for the last 3 months is 33,112,016 and the stock's 52-week low/high is $0.000099999/$0.01195.

eWellness Healthcare Corp. (EWLL)

Penny Stock Prodigy and StockHideout reported earlier on eWellness Healthcare Corp. (EWLL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Culver City, California-based eWellness Healthcare Corp. develops a telemedicine platform. This platform is for providing Distance Monitored Physical Therapy programs. These programs are for pre-diabetic, cardiac, and health challenged patients via contracted physician practices and healthcare systems. The Company has launched PHZIO. The design of this telemedicine platform is to extend and scale a physician’s practice. eWellness Healthcare is the first physical therapy telemedicine enterprise to provide insurance reimbursable real-time distance monitored treatments. eWellness Healthcare lists on the OTC Markets Group’s OTCQB.

The Company’s business model is to license its PHZIO platform to any physical therapy (PT) clinic in the United States and/or have large-scale employers use its PHZIO platform as a completely PT monitored corporate wellness program. eWellness Healthcare’s PHZIO is a Physical Therapy Telemedicine platform. It extends a traditional practice online.

The chief features of the PHZIO platform include video treatment protocols, real-time patient monitoring, patient induction forms, a patient video journal, and post treatment evaluations. In addition, main features include integrated billing, patient metrics, and user administration & customization.

Moreover, PHZIO scales a practice’s billable rates. It also provides tools to make growing a business easier. Pertaining to the Patient Dashboard, the PHZIO Dashboard enables clients to login securely to access prescribed treatment protocols. PHZIO is user-friendly and highly reliable to operate for PT and Patient. Furthermore, it’s a total on-line PT telemedicine intervention system.

eWellness Healthcare has launched a PHZIO PT clinic on-boarding website. The site includes a telehealth profitability calculator to illustrate to prospective PT clinics the additional profits they can make through using the PHZIO platform.

eWellness Healthcare anticipates adding Artificial Intelligence (AI) tools and predictive analytics into its PHZIO platform by the end of this year. The anticipation is that the new AI and predictive analytics will combine the Company’s existing remote monitoring capabilities with machine learning and intelligent analytics, which take advantage of patient health data to improve healthcare outcomes.

Evolution Physical Therapy has added eWellness Healthcare's Telehealth PT Services at its four clinical locations in Los Angeles, California. This includes Culver City, Playa Vista, Beverly Hills, and Brentwood. Mr. Darwin Fogt, Chief Executive Officer of eWellness Healthcare, owns Evolution Physical Therapy.

Recently, eWellness Healthcare and Total Release Physical Therapy announced an Integration & Marketing Agreement. Total Motion Release Seminars (TMR) is a proprietary physical therapy methodology developed by Mr. Tom Dalonzo-Baker, MPT. TMR is a full-body oriented assessment and treatment approach. TMR helps patients lessen their pain and impairments which limit their function. The treatment approach is created to allow physical therapists to interact and treat their patients remotely. The expectation is that integration with PHZIO will be extensively adopted within the TMR community.

eWellness Healthcare Corp. (EWLL), closed Friday’s trading session at $0.0008, up 100.00%, on 3,012,132,830 volume with 1,675 trades. The average volume for the last 3 months is 368,476,238 and the stock's 52-week low/high is $0.000000999/$2.00.

The QualityStocks Company Corner

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF)

The QualityStocks Daily Newsletter would like to spotlight Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF).

Investment holding company Clean Power Capital (CSE: MOVE) (OTC: MOTNF) (FWB: 2K6A) welcomed a California proposal to allocate $1.5 billion to the construction and maintenance of charging and hydrogen fueling infrastructure. According to a company press release, California Governor Gavin Newsom’s proposal to earmark these funds as part of a $4.5 billion stimulus proposal for the 2021 state budget is encouraging for Clean Power Capital and its investee PowerTap’s hydrogen station plans (https://ibn.fm/5cToG).

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) is an investment holding company that focuses on investing in and providing early-stage financing to both public and private businesses. Since its original listing with the Canadian Stock Exchange (“CSE”) on January 23, 2019, the company has made investments in a number of different businesses in a variety of industries, including the energy and cannabis sectors. As per the company’s investment policy, its primary goal is to identify and capitalize on high-return investment opportunities presenting the ability to achieve capital appreciation and liquidity.

Clean Power Capital continues to be opportunistic in evaluating prospects across the renewable energy, bio-medical, pharmaceutical and naturopathic sectors, both as an investor and as an operator. The company’s main focus at the moment is to identify such opportunities in the renewable energy industry, including wind, solar and geothermal power and hydrogen and fuel cell technologies, as well as in the biomedical, pharmaceutical and naturopathic sectors, which may include medical or recreational cannabis.

Clean Power Capital currently has 10 investments in a variety of sectors and successfully held nearly C$120 million in investments during the past fiscal year (https://ibn.fm/8oktZ). It returned capital to its shareholders through the distribution of its interest in AgraFlora Organics International Inc. in May 2020 (https://ibn.fm/FRAvq).

Headquartered in Vancouver, British Columbia, Clean Power Capital was formerly named Organic Flower Investments Group Inc. As of November 10, 2020, the company officially changed its name to Clean Power Capital and started trading on the CSE under new ticker symbol ‘MOVE’.

PowerTap Acquisition, Hydrogen Fueling Infrastructure Collaboration

In alignment with its updated investment policy, a reconstituted investment committee and a revised strategy to reflect its focus on the renewable energy market, Clean Power Capital recently completed the acquisition of a 90 percent equity interest in California-based PowerTap Hydrogen Fueling Corp.

Leveraging an impressive portfolio of IP and advanced deployed technologies developed over two decades via substantial investments and partnerships, PowerTap is working on building and expanding a hydrogen filling station network, initially across North America. The company believes that its platform has a significant advantage over other hydrogen fueling stations, because it has a smaller physical footprint and further has the capacity to produce hydrogen fuel on site. As most other hydrogen fueling stations buy hydrogen for storage at higher costs, PowerTap’s model is believed to be exponentially more cost-effective and expandable.

Clean Power Capital’s investment and acquisition will allow PowerTap to step up its efforts and begin work on the hydrogen fueling station network in stages, starting with engineering and design, ongoing development of PowerTap’s third generation product and, finally, licensing & permitting and site preparation. Development is expected to begin in Q4 2021 with engineering and design. Overall, the initial portion of the project is expected to cost $17 million, with Clean Power Capital and PowerTap planning to secure government financing and credit, as well as equity, debt and convertible debt offerings, to fund the infrastructure’s development.

PowerTap technology is already deployed across multiple hydrogen fueling stations in public and private enterprises spanning California, Maryland, Massachusetts and Texas. The company plans to deploy its hydrogen fueling infrastructure at existing truck stops and gas stations across the country, beginning with up to 1,000 stations within the next three to five years. At the moment, there are roughly 70 active hydrogen fueling stations operational and available to consumers in the United States.

Hydrogen Industry Outlook

The project is expected to bring significant opportunities for PowerTap and Clean Power Capital on the fast-growing hydrogen market, driven by a worldwide focus on clean energies and environmentally friendly fueling solutions for the transportation industry.

Hydrogen-powered vehicles come with tremendous advantages over gas, diesel and even electric vehicles in terms of cost per mile, fueling time and driving range, as well as boasting significantly lower emissions. Well-established vehicle manufacturers such as Hyundai, Toyota, Daimler and Volvo are already including hydrogen-powered cars in their product lineups, and Nikola Motors has announced plans to manufacture hydrogen electric long-haul vehicles.

“As an experienced developer of technology in an important area that is finally having its time as a green but also economically compelling energy option, PowerTap is intent on becoming a leading part of the multi-billion dollar hydrogen fueling space,” PowerTap CEO Raghu Kilambi explained in a news release on October 28, 2020 (https://ibn.fm/oaXem).

A recent industry report developed by a coalition of major oil and gas, power, automotive, fuel cell and hydrogen companies indicates that the sector is expected to grow to $140 billion a year in revenue by 2030, creating 700,000 jobs in the U.S. alone (https://ibn.fm/UMI5q). According to Fuel Cell and Hydrogen Energy Association President Morry Markowitz, the sector could expand to $750 billion a year in revenue and 3.4 million jobs by 2050.

The U.S. is already engaged in the hydrogen economy, having more than half of the global number of fuel cell vehicles and investing hundreds of millions of dollars a year, but the country can greatly expand its global energy leadership by scaling up operations in the hydrogen economy, per the industry report.

With the upcoming change in administration in January 2021, the U.S. is expected to renew its commitment to clean energy. Moreover, the U.S. federal government is expected to invest significantly in clean energy and related infrastructure, including hydrogen, according to PowerTap.

“As the U.S. federal government has previously invested in the PowerTap technology, we are optimistic that we will have a seat at the table when USA clean energy/hydrogen infrastructure spending initiatives are designed,” Kilambi added.

Management Team

Joel Dumaresq is the CEO and interim CFO of Clean Power Capital. He is a proven executive with extensive operational and senior management experience in mining, energy and alternative energy, as well as the cannabis and hemp space. Dumaresq began his career in the corporate finance space, having spent 12 years with RBC Dominion Securities. He brings 30 years of experience in the financial sector to the company, has been instrumental in raising over $250 million in venture capital finance, and he has personally managed a number of successful public listings.

Brendan Purdy serves as a director of Clean Power Capital. An experienced businessperson who has led five different companies, Purdy brings years of experience in different industries, including cannabis, blockchain and data security, gaming, mining and energy, and finance and law. He received a graduate degree from the University of Ottawa and an undergraduate degree from the University of Western Ontario.

Theo van der Linde serves as a director of Clean Power Capital. He is a Chartered Accountant with over 20 years extensive experience in finance, reporting, regulatory requirements, public company administration, equity markets and financing of publicly traded companies. He has served as a CFO & Director for a number of TSX Venture Exchange- and Canadian Securities Exchange-listed companies over the past several years. His industry experience spans the financial services, manufacturing, oil & gas, mining and retail industries. More recently, van der Linde has been involved with future use trends of natural resources, as well as other disruptive technologies.

Raghu Kilambi is the CEO and CFO of PowerTap Hydrogen. He is a seasoned investor and entrepreneur with over 25 years of global business experience in public and private investments, building businesses and creating shareholder value. He has raised over $1 billion of equity and debt capital for private and public companies and been involved in many M&A acquisitions and exits.

Clean Power Capital Corp. (OTC: MOTNF), closed Friday’s trading session at $2.51, up 5.4622%, on 319,044 volume with 271 trades. The average volume for the last 3 months is 245,853 and the stock's 52-week low/high is $0.0315/$2.78999996.

Recent News

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF)

The QualityStocks Daily Newsletter would like to spotlight Canopy Rivers Inc. (RIV) (CNPOF).

Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF) was highlighted today in a publication from FinancialNewsMedia.com, examining how revenue projections for the recreational and medical marijuana markets keep rising, each one larger than the previous studies. According to a recent report by ArcView Market Research and BDS Analytics, the global licensed dispensary sales of cannabis will reach $40.6 billion by 2024, registering a CAGR of 24.5%.

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) is the venture capital investment platform of Canopy Growth Corporation (TSX:WEED, NYSE:CGC).

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers collaborates with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. Headquartered in Toronto, Canada, Canopy Rivers has developed an ecosystem of complementary cannabis operating companies operating throughout the cannabis value chain.

Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.

Canopy Rivers’ expanding portfolio includes:

  • Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.
  • CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.
  • Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.
  • James E. Wagner Cultivation Ltd. (TSXV:JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.
  • LiveWell Foods Canada Inc. (TSXV:LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.
  • PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.
  • Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.
  • Solo Growth (TSXV:ALZ) is a new cannabis retail concept that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Solo Liquor Stores Ltd., a leading Canadian liquor retailer. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy.
  • Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.
  • TerrAscend Corp. (CSE:TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.
  • Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.

As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.

Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.

Canopy Rivers Inc. (CNPOF), closed Friday’s trading session at $1.55, up 0.649351%, on 233,296 volume with 437 trades. The average volume for the last 3 months is 502,976 and the stock's 52-week low/high is $0.371499985/$1.64999997.

Recent News

AzurRx BioPharma Inc. (NASDAQ: AZRX)

The QualityStocks Daily Newsletter would like to spotlight AzurRx BioPharma Inc. (NASDAQ: AZRX).

AzurRx BioPharma Inc. (NASDAQ: AZRX) was featured today in a publication from PennyStocks.com, examining how, despite the market starting low in the morning, by midday, many penny stocks were up on January 22nd. There are a lot of factors influencing the stock market today. With lower-priced stocks, volatility continues playing a big role. With so many different investing styles out there, this can be a major benefit to some but pose a big risk to others. Right now, we are seeing heightened popularity across several industries. This includes tech, biotech, and energy penny stocks . With the pandemic still in full swing, we have to consider how these industries could be affected. For biotech penny stocks , the effect is quite obvious, but it differs depending on if the company is involved in vaccine treatments or not.

AzurRx BioPharma Inc. (AZRX) is a clinical-stage biopharmaceutical company focused on developing treatments for gastrointestinal diseases using recombinant proteins.

The company’s lead drug candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients suffering from cystic fibrosis and chronic pancreatitis.

AzurRx has already completed two Phase 2 clinical trials for MS1819 and is currently pursuing approval through parallel monotherapy and combination therapy pathways.

The company was founded in 2014 and is headquartered in New York City, with scientific operations in Langlade, France, and clinical operations in Hayward, California.

MS1819 Clinical Trials

The two current ongoing clinical trials for MS1819 in cystic fibrosis (CF) are the Phase 2b Option 2 monotherapy trial and the Phase 2 combination therapy trial, using MS1819 together with porcine pancreatic enzyme replacement therapy (PERT), the current standard of care. Pending the Phase 2b trial outcome, the company intends to initiate a Phase 3 trial in cystic fibrosis.

  • Phase 2b CF Option 2 Trial – The study was initiated in Q3 2020, using MS1819 doses in enteric capsule form (2240mg and 4480mg). Topline data for the trial is anticipated in Q1 2021.
  • Phase 2 CF Combination Trial – The study was initiated in Q4 2019, using daily dose levels of PERT in combination with MS1819 dosages (700mg, 1120mg and 2240mg). Topline data is anticipated in Q2 2021.

These trials are currently addressing the treatment of EPI in patients with cystic fibrosis and chronic pancreatitis – an established global market with an estimated value in excess of $2 billion that has been growing at a CAGR greater than 20% over the past five years.

Results from AzurRx’s Phase 2b Option 2 trial of MS1819 in cystic fibrosis patients demonstrate that the non-porcine MS1819 lipase is well-tolerated by patients, with no significant safety signals observed at the 2240mg daily dose level.

“[W]e have evaluated four different enteric capsules and identified the best suitable formulation for MS1819 that provides gastroprotection of enzyme content and delayed release into the duodenum,” James Sapirstein, President & CEO of AzurRx, stated in a September 2020 news release (https://ibn.fm/27t4W). “Our clinical program continues to advance, and we are determined to develop MS1819 as a safer alternative to porcine pancreatic enzyme replacement therapy, significantly reducing the pill burden of cystic fibrosis patients.”

Financial Highlights

As of July 2020, AzurRx had raised gross cash capital of $22.1 million, including $15.2 million from Series B convertible preferred stock and warrants in July 2020 and $6.9 million from convertible promissory notes and warrants in December 2019 and January 2020. Notably, AzurRx solidified its financial position and created an effectively debt-free balance sheet by exchanging substantially all of its outstanding convertible notes into the Series B convertible preferred stock financing.

The company secured an additional $2.5 million in French Research Tax Credits, received in 2020, for the years 2017-2019 (https://ibn.fm/Qxk7O).

In a letter to shareholder, Sapirstein noted that ensuring the company maintains sufficient capital to support its business operations has been a key focus. He further stated that the company is in “a financially secure position” to complete its two Phase 2 MS1819 clinical trial programs and to begin preparations in 2021 for a pivotal Phase 3 study.

The company has no current plans to access additional financing, as it believes it has enough cash to fund existing operational and clinical objectives through Q3 2021.

Management Team

James Sapirstein is the President and CEO of AzurRx BioPharma. He was previously the CEO and a board member for ContraVir Pharmaceuticals Inc., which is now known as Hepion Pharmaceuticals Inc. (NASDAQ: HEPA). Mr. Sapirstein has almost 36 years of experience in the pharmaceutical industry, with expertise in drug development and commercialization. He currently serves on the Emerging Companies and Health Section boards of the BIO (Biotechnology Innovation Organization) and is Chairman Emeritus of BioNJ. He earned his Bachelor’s degree in Pharmacy from Rutgers University and has an MBA in management from Fairleigh Dickinson University.

Daniel Schneiderman is the Chief Financial Officer of AzurRx. He previously served as the CFO of Biophytis SA and its U.S. subsidiary, Biophytis, Inc., clinical-stage biotechnology companies focused on the development of pharmaceutical candidates for age-related diseases. He was appointed to the AzurRx position in January 2020, bringing to the team over 18 years of experience in capital markets and finance operations. Mr. Schneiderman holds a degree in economics from Tulane University.

James Pennington, M.D., is the Chief Medical Officer of AzurRx. Before joining the team, he was the Chief Medical Officer and Senior Clinical Fellow for 11 years at Anthera Pharmaceuticals. Before becoming a part of the biotech industry, Dr. Pennington was on the Medical Faculty of Harvard Medical School for 10 years. He received his medical degree from Oregon Health & Science University.

Martin Krusin is the Senior Vice President for Corporate Development at AzurRx. He has 20 years of experience in business development, strategic marketing, financing and operations in the health care, financial services and consulting sectors. Before joining AzurRx, he was the VP for Business Development at FluoroPharma Medical Inc. Mr. Krusin received his MBA from Columbia Business School in finance and marketing, an MPhil. in political economy from Oxford University and a BA in international relations from Swarthmore College.

Dinesh Srinivasan, Ph.D., is the Vice President for Translational Research at AzurRx. He has over 15 years of experience leading drug discovery and development in the pharmaceutical industry. He began his career as a post-doctorate fellow at Roche Palo Alto. Dr. Srinivasan received his MSc in Biotechnology from the University of Mumbai, India, and a Ph.D. in Pharmacology and Toxicology from the University of Arizona – Tucson.

Ted Stover is the Product Development Director at AzurRx. He joined the company in 2020 to oversee CMC and Project Management. Before joining AzurRx, he spent 20 years focused on manufacturing operations and analytical method development for all stages of pharmaceutical drug development. Mr. Stover earned his MBA from the University of Florida.

AzurRx BioPharma Inc. (AZRX), closed Friday’s trading session at $1.84, up 48.3871%, on 179,230,859 volume with 277,130 trades. The average volume for the last 3 months is 5,406,591 and the stock's 52-week low/high is $0.370867997/$2.63000011.

Recent News

Brain Scientific Inc. (OTCQB: BRSF)

The QualityStocks Daily Newsletter would like to spotlight Brain Scientific Inc. (OTCQB: BRSF).

Brain Scientific Inc. (OTCQB: BRSF) was featured today in a publication from BioMedWire, examining how a study conducted in 2017 forecasted that artificial intelligence (AI) could extensively improve health-care results by 30–40%. AiVF, an Israeli ML company, has suggested that artificial intelligence bears the potential to grow the success rate of IVF by almost three times when compared to conventional methods. It should be noted, however, that pregnancy is dependent on other factors, such as age.

Brain Scientific Inc. (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. With a mission of modernizing brain diagnostics by employing cutting edge technologies to bridge the widening gap in access to quality care, the company offers two FDA-cleared products that provide next-generation solutions to the neurology market.

The company’s proprietary, clinical-grade neurological devices are supported by its intellectual property portfolio featuring patents in the United States, China and Europe.

Brain Scientific’s first commercialized devices, NeuroCap(TM) and NeuroEEG(TM), are designed to disrupt the current electroencephalogram (EEG) market by offering cost-effective and disposable substitutes to existing solutions, allowing medical professionals to collect diagnostic information quickly.

The company’s goal is to improve diagnostics by leveraging artificial intelligence and machine learning processes to analyze a database of brain readings as a method of detecting seizures and dementia. The company is also working to improve patients’ access to neurological care.

Headquartered in New York, Brain Scientific and its predecessor (and now wholly owned subsidiary, MemoryMD Inc.) was founded in 2015 and went public in 2018.

Brain Scientific’s first phase of development, from 2018 to 2019, saw the inception of portable, clinical-grade, easy-to-use neurological devices. The second phase, currently ongoing, aims to create cloud-based, secure infrastructure to transmit patient data between patients and their neurologists. The company’s third phase of development is scheduled for 2021-2022 and is expected to focus on the use of AI-assisted diagnostic analysis to increase the efficiency, consistency and accuracy of neurology specialists.

NeuroCap(TM) – Disposable EEG Headset

The NeuroCap is a disposable pre-gelled EEG headset featuring 22 electrodes and 19 active EEG channels, all adhering to the international 10-20 system. The NeuroCap was FDA-cleared in 2018. The headset can be used for recording EEGs in virtually any setting, including urban and rural emergency departments, neurology clinics, urgent care clinics, ICUs, nursing homes, assisted living facilities and remote clinical research labs.

Through a universal cable adapter, the NeuroCap is compatible with other EEG amplifiers. The cap also works in parallel with Brain Scientific’s NeuroEEG amplifier, initiating EEG studies in less than five minutes.

The company is currently seeking FDA approval for additional features for the NeuroCap, as the device has the potential to fill a gap in EEG testing availabilities during the current coronavirus pandemic: in October 2020, Brain Scientific filed an Emergency Use Authorization (EUA) application. The EUA is required for the rapid distribution of the NeuroCap device to emergency departments, intensive care units and other treatment centers to administer prescriptive EEGs safely on critically ill patients or those suspected of being diagnosed with COVID-19.

With more than 80 percent of hospitalized patients infected with COVID-19 displaying neurological symptoms, the NeuroCap could prove to be a valuable device by offering fast testing with limited contact between technicians and patients.

NeuroEEG(TM) – Miniature and Portable Wireless EEG Amplifier

The NeuroEEG is a compact, portable and affordable wireless EEG amplifier intended for prescription use. The 16-channel, FDA-cleared, clinical-grade device acquires, records, transmits and displays electrical brain activity for patients of all ages.

Both the NeuroCap and NeuroEEG are delivered by MemoryMD Inc., a wholly owned subsidiary of Brain Scientific.

Products in Active Development

Currently, Brain Scientific and MemoryMD are working on leveraging their existing products and drawing from ongoing research to develop and commercialize the next generation of solutions for the brain diagnostics market. The devices under development are being designed to address the following issues:

Routine EEG

  • NeuroCap-8 is an 8-channel EEG cap. The reduced number of electrodes is vital in emergency room situations, where the time it takes to set up the EEG is critical.

Pediatric EEG

  • NeuroCap Pediatric is positioned to become the first disposable and pre-gelled headset available for the pediatric market.

Long-Term Monitoring

  • NeuroCap LTM for adult and pediatric patients is a disposable cap designed to monitor rhythmic and periodic patterns for up to 72 hours, providing essential diagnostic capabilities.
  • NeuroEEG 24 Channel Amplifier is a portable and wireless amplifier with over 24 hours of battery life.

Artificial Intelligence

  • Brain E-Tattoo is a minimally invasive four-channel EEG electrode designed for long-term monitoring.
  • An AI database of brain biomarkers collects data on both normal and abnormal brain data to detect neurological diseases. The goal is for machine learning algorithms to enhance understanding of brain-behavior related to epilepsy, memory dementia and pre-Alzheimer’s diagnostics.

Telemedicine

Brain Scientific is expanding the vision for telemedicine in neurology. The company aims to address the current acute neurologist shortfall (20 states have less than 10 neurologists per 10,000 patients) through the use of teleneurology.

 

Partnership with Marketing Brainology

Brain Scientific has a longstanding partnership with Marketing Brainology, a neuromarketing firm using neuroscience approaches to understand consumer behavior. In 2019, Marketing Brainology conducted a study using NeuroCap and NeuroEEG to determine the most effective Super Bowl commercials.

“Thanks to Brain Scientific’s NeuroCap and NeuroEEG, we are able to better understand the art and science of the human decision-making process,” Michelle Adams, Ph.D, Founder of Marketing Brainology, stated in a news release.

In April 2020, Marketing Brainology again conducted a study leveraging Brain Scientific’s disposable EEG cap to determine how brains were reacting to COVID-19 messaging. Subjects were presented with multiple media impressions, and Marketing Brainology analyzed their responsive biomarkers. The results identified the most effective messaging for engaging with an audience during a crisis.

Market Outlook

The current global market for EEG devices is estimated at $956.1 million. It is expected to rise with a CAGR of 8.7% from 2019 to 2026, reaching $1.6 billion in value by 2026, according to Grandview Research.

In total, there are approximately 6,150 hospitals in the U.S., according to the American Hospital Association. Critically, though, just 254 of those hospitals are certified Level 4 Epilepsy centers with 24/7 EEG coverage. Since very few non-Level 4 centers have extensive EEG tech coverage, this creates a significant opportunity for Brain Scientific to bridge the gap by providing over 5,900 hospitals with lower cost amplifiers and disposable EEG caps.

The company also see opportunities to work with other businesses, such as EEG manufacturers hoping to package Brain Scientific’s solutions with their products, which could greatly expand Brain Scientific’s addressable target market.

Management Team

Dr. Baruch “Boris” Goldstein, Ph.D., is co-founder and Chairman of Brain Scientific. He is a seasoned executive with a proven talent for aligning global business strategies with established and emerging management teams. Goldstein’s growth-focused leadership style has helped him raise over $750 million in venture capital for the development of innovative companies and startups in diverse industries, including financial services, biomedicine, alternate energy and new materials, as well as groundbreaking work in artificial intelligence. His recent achievements include important advancements in neurology and unlocking the potential of AI correlations and machine learning applied to life sciences and medical research. He built a suite of first-to-market companies as a technology-oriented leader, including Ryah Medtech, Brain Scientific, GrapheneCA, E-Forex and Intelligent Video Systems. He also co-founded BrainRX, a company specializing in pre-Alzheimer’s diagnostics.

Dr. Nikolay Kukekov, Ph.D., is a Director of Brain Scientific and a partner at HRA Capital. Before joining HRA Capital, Kukekov was Managing Director of Healthcare Investment Banking at Summer Street Research. His scientific background includes a bachelor’s degree in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder. He earned his Ph.D. in neuroscience from Columbia University – College of Physicians and Surgeons in New York.

Stuart Bernstein is the company’s Vice President of Marketing. He was recently named to the role after spending the first part of his professional career in senior technical management roles with Fortune 500 companies such as NCR (NYSE: NCR), IBM (NYSE: IBM) and Control Data Corp. He was the CEO of BioSignal, an EEG medical device company. He is also a co-founder of several software engineering and telemedicine firms. One of them, Brain Saving Technology, is now Specialist on Call (SOC Telemed) – a leading telemedicine company that powers over 850 facilities for teleneurology, telepsychiatry and critical care telemedicine with over 200 physicians.

Brain Scientific Inc. (OTCQB: BRSF), closed Friday’s trading session at $1.49, up 10.3704%, on 12,944 volume with 30 trades. The average volume for the last 3 months is 18,880 and the stock's 52-week low/high is $0.100000001/$3.00999999.

Recent News

The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER)

The QualityStocks Daily Newsletter would like to spotlight The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER).

More than a year after the coronavirus pandemic emerged in Wuhan, China, and brought the world to its knees, scientists have successfully developed a COVID-19 vaccine. However, demand for the vaccine far outweighs the supply, forcing governments to implement vaccination programs in phases and vaccinate their populations based on urgency and priority. In the United States, essential workers are among those given first priority, and cannabis companies have argued that because as their employees are on the frontline, they ought to be vaccinated as well.

Founded in 2012, The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88®, is a leading premier alkaline water brand available in bulk and single-serve sizes, along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88® delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts the company’s trademarked label ‘Clean Beverage’. Quickly being recognized as a growing lifestyle brand, Alkaline88® launched A88 Infused™ in 2019 to meet consumer demand for flavor-infused products. A88 Infused™ flavored water is available in six unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched the A88CBD™ brand, featuring a broad line of topical and ingestible products. These products are made with lab-tested full and broad-spectrum hemp and include salves, balms, lotions, essential oils, bath-salts, CBD infused drinks, tinctures, capsules, gummies and powder packs.

Innovation and Expansion

Founded in 2012, The Alkaline Water Company began with a mission to create the best-tasting water in the world. At the time, there were two emerging trends in health-conscious consumers: a growing interest in the alkaline diet and perceived health benefits of pink Himalayan rock salt. By combining these two concepts in an alkaline water and trademarking the name Alkaline88, The Alkaline Water Company began offering what it calls the smoothest tasting Clean Beverage™ in the U.S. enhanced-water category.

Now a top bulk alkaline-water brand (the company reported record sales in March and April 2020, surpassing March and April 2019 numbers by 114% and 171%, respectively), The Alkaline Water Company is committed to growing its national footprint through innovation and expansion. That mindset was evident as the company introduced eco-friendly aluminum bottles and branched out into flavor-infused waters; the company currently offers six different flavors: peach/mango, lemon/lime, raspberry, watermelon, blood orange and lemon.

The company’s commitment to innovation may be most evident in its newest product line: A88CBD. This line of CBD-infused products includes tinctures, capsules, gummies, salves, balms, hand and foot lotions, essential oils, bath bombs and bath salts, as well as CBD-infused drinks, water and beverage shots. These quality, CBD-infused offerings are all made with lab-tested, full-spectrum hemp and are conveniently packaged and perfect for on-the-go or at home use.

In addition, The Alkaline Water Company has implemented an aggressive growth strategy, with numerous organic initiatives focused on national multichannel, mass-market expansion through a direct-to-warehouse model and co-packing facilities that are strategically located within 600 miles of 95% of the U.S. population. In addition to this strong brick-and-mortar approach, the company recently launched a B2C e-commerce platform (www.A88CBD.com) and aggressive digital-marketing campaigns.

Clear Advantages in a Growing Market

With consistent growth year over year, the company reported $32.2 million in revenue in fiscal 2019 and has emerged as a growth leader in the functional (value-added) waters space, which is the fastest-growing segment of the bottled water industry.

The Alkaline Water Company’s efforts are focused on its clear competitive advantages, including its strong marketing (the inclusion of alkaline in product names); existing grocery channels, which feature excellent relationships and a nationwide broker network; distinctive branding; proprietary technology, which produces great-tasting, high-quality water, infused drinks and other products; and price, with a broad range of products in all formats, from bulk bottles to single serve.

As the company focuses on strategic growth, it is eyeing the impressive potential of a market that is on a strong upswing. Annual bottled water sales have now surpassed soda consumption, with soda sales in the United States having declined by $1.2 billion over the past five years. Some research indicates that the global bottled water market will reach an estimated $280 billion this year, while the CBD market is forecast to top $20 billion by 2024.

With its products available in all major trade channels, including grocery stores, drug stores, c-stores and big-box retailers, The Alkaline Water Company is also looking to expand into new spaces, such as health and beauty, hospitality and specialty retailer locations.

Seasoned Management Team

The Alkaline Water Company is led by an experienced team focused on the company’s core strategy of building a national retail footprint and extending its lifestyle brands into other consumer packaged goods categories.

Richard A. Wright, President, CEO and Co-Founder of The Alkaline Water Company Inc., oversees all aspects of the business, successfully guiding the company through strategic opportunities and delivering greater than 50% growth since the company’s inception. A passionate and versatile leader with a strong track record of innovation, collaboration and achieving goal-driven results, Wright is a serial entrepreneur with more than 41 years of experience. Early in his career, he spent years at one of the ‘Big Four’ accounting firms, working his way up to Regional Director of Tax and Financial Planning. As a CPA, entrepreneur and former CFO, Wright brings extensive knowledge of finance, operations, sales and marketing to the team, and he has participated in hundreds of M&A transactions throughout his career.

David Guarino, CFO, Secretary, Treasurer and Director, earned a Bachelor of Science in accounting and a Master of Accountancy from the University of Denver. From 2008 to 2013, Guarino was President and a Director of Kahala Corp., a worldwide franchisor of multiple quick-service restaurant brands with locations in 49 states and more than 25 countries. From 2014 to 2015, Guarino was President of HTI International Holdings Inc., a technology company focused on forward osmosis water filtration technology.

Frank Chessman, National Sales Manager, is a graduate of the University of Southern California’s Marshall School of Business. He spent 25 years with Ralph’s Grocery, Kroger’s largest division, working at many levels before ultimately becoming Vice President of Advertising & Marketing. He then served 14 years as Executive Vice President at Simon Marketing. Chessman has more than a decade of experience in the beverage manufacturing industry.

Brian Sudano, Director, is managing partner of Beverage Marketing Corporation and BMC Strategic Associates. Sudano’s experience covers nearly the entire beverage industry, from energy drinks to wine, with special expertise in beverage alcohol by virtue of varied industry experience across a broad range of projects. Sudano manages several major clients, providing ongoing strategic and market advice and leading projects in strategic planning, market entry analysis and planning, sales/distribution, business modeling, brand repositioning and international opportunity assessment. He has spoken at many beverage industry events and is a contributing editor at Beverage World magazine.

Aaron Keay, Chairman, has been a successful investor, entrepreneur and financier to multiple small cap and startup companies over the last decade. During his time with these companies, he served in advisor, board-member and senior-management roles. His experience ranges across multiple sectors in mining, biotech, health and wellness, tech and cannabis, where he has invested and raised more than $500 million.

The Alkaline Water Company Inc. (NASDAQ: WTER), closed Friday’s trading session at $1.24, up 7.8261%, on 6,700,069 volume with 11,250 trades. The average volume for the last 3 months is 1,863,377 and the stock's 52-week low/high is $0.400000005/$2.5999999.

Recent News

Green Hygienics Holdings Inc. (OTCQB: GRYN)

The QualityStocks Daily Newsletter would like to spotlight Green Hygienics Holdings Inc. (OTCQB: GRYN).

As Green Hygienics Holdings (OTCQB: GRYN) wraps up its first successful crop harvest and enters the wholesale retail stage of development, the company has engaged the services of McAllister Garfield, PC, a top law firm in the industrial hemp space. GRYN, an innovative technology-driven enterprise focused on the high-standard cultivation and processing of industrial hemp and manufacturing of pharmaceutical-grade bioactive cannabinoids, made the decision in anticipation of rapid growth in 2021. Also today, the company was featured in the 420 with CNW by CannabisNewsWire.

Green Hygienics Holdings Inc. (OTCQB: GRYN) is a California-based innovative technology-driven enterprise focused on the high standard cultivation and processing of industrial hemp and manufacturing of pharmaceutical-grade bioactive cannabinoids.

The company aims to be a leader in compliance and capabilities in the hemp and cannabinoid supply marketplace. By leveraging state of the art technologies, the company intends to open up a whole new world of novel cannabinoids and targeted bio-delivery technologies never before explored, solving the issues of stability, pharmacokinetics, biological tissue penetration and bioavailability.

Dedicated to creating the hemp industry’s safest and finest quality products, the company will be uniquely positioned to deliver product efficacy and supply chain solutions to consumers, as well as to leverage these within its own products and brand portfolio.

USDA Organic Certification and FDA Registration

On August 26, 2020, Green Hygienics registered with the U.S. Food and Drug Administration pursuant to the Federal Food Drug and Cosmetic Act, as amended by the Bioterrorism Act of 2002. This registration strengthens the company’s core mission to provide product efficacy to the pharmaceutical industry and consumers alike.

On September 30, 2020, Green Hygienics was granted USDA Organic Certification (7 CFR Part 205) for the cultivation and post-harvest processing of industrial hemp by the California Certified Organic Farmers for its Sol Valley Ranch property. This certification further enables the company to supply certified organic hemp products to national and international markets.

Market Opportunity

Green Hygienics is focused on finding, acquiring and developing strategically positioned businesses, as well as the best innovations within the hemp industry – a fast-progressing market with remarkable opportunities for growth. The industrial hemp market is expected to reach $5.33 billion in 2020 and is projected to rise to $15.26 billion by 2027, achieving a CAGR of 15.8%, per Grand View Research.

Capital Structure

GRYN has less than 42 million shares outstanding, fully diluted. The company has just 7.2 million common shares in float and boasts a balance sheet with no toxic debt or overhang.

Key Management

Dr. Levan Darjania serves as the company’s Chief Science Officer. Darjania has over 26 years of experience in biotechnology and pharmaceutical drug development. His research and development experience has led him to develop many in-house and collaborative R&D programs over the course of his career.

Kyle MacKinnon serves as GRYN’s Chief Operating Officer. He has extensive knowledge in cannabis processing and was previously the Business Development Manager of Advanced Extraction Systems Inc., a leader in CO2 Supercritical Fluid Extraction. MacKinnon brings over 20 years of sales and management experience to the company.

Ronald Loudoun is the President, CEO, Secretary and Director of Green Hygienics. He received an undergraduate business degree from the British Columbia Institute of Technology. Before joining Green Hygienics, he was the founder and a director of renewable energy firm Archer CleanTech Inc.

Jerry Halamuda is the Senior Vice President of Business Development of the company’s Agriculture Division. He has an extensive career working in the agriculture and horticulture industry. Halamuda has founded, managed and operated multiple successful companies, including Color Spot Nurseries.

John Gildea is GRYN’s Senior Vice President of Corporate Development. He has over 20 years of experience working within the private and public markets. His expertise includes negotiating and structuring private and public financing and mergers. During the course of his work, Gildea has established trusted relationships with a network of equity and capital partners.

 

Green Hygienics Holdings Inc. (OTCQB: GRYN), closed Friday’s trading session at $0.84, up 2.439%, on 21,607 volume with 14 trades. The average volume for the last 3 months is 20,674 and the stock's 52-week low/high is $0.300000011/$2.00.

Recent News

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF)

The QualityStocks Daily Newsletter would like to spotlight GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF).

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) was featured today in a publication from MiningNewsWire, examining how Dr. Toan Dinh is a mechanical engineer from Australia who has found a way to help avert death and injury on mining sites. His method involves the use of new sensors created using silicon carbide to detect early mechanical issues in gas and oil pipelines. Dinh, an engineer from the University of Southern Queensland, has spent the last 6 years creating these sensors whose objective is to identify impending danger in corrosive as well as harsh environments. Also today, the company was featured in a MiningNewsBreaks from BioMedWire, examining how has announced it is working to complete preparations for 5000m Phase 1 drilling to begin on its Rio Loa property. In addition, the company is preparing to conduct trenching programs at its Coya, Alicia and Roma projects; those programs will include rock sampling and geophysics. The company reported that earlier trenching conducted at Rio Loa exposed hydrothermal breccias, a key finding because hydrothermal breccias form host rocks to gold and silver mineralization found in deposits similar to Gold Field's Salares Norte project, which is located 25km to the north of GOH’s Rio Loa property. To view the full press release, visit https://ibn.fm/qf06r

GoldHaven Resources Corp. (CSE: GOH) (OTCQB: GHVNF) (formerly Altum Resources Corp.), a Canada-based company engaged in the business of acquiring and exploring mineral resource properties, recently announced its entry into agreements to acquire seven advanced gold projects in the Maricunga Gold Belt of Chile that hosts over 100 million ounces of gold within the last 10 years.

Chilean Gold Properties Being Acquired

On April 17, 2020, GoldHaven Resources entered into an agreement to purchase a 100% interest in two gold projects located in the Maricunga Gold Belt of Northern Chile. The first property, Rio Loa, is located 25 kilometers south of Gold Fields Ltd.’s Salares Norte, where, this year, a five-million-ounce discovery was made. The second property, Coya, is located only 10 kilometers east of the Kinross La Coipa open pit mine, which has produced over 7.5 million ounces of gold to date.

Rio Loa Project

Initial geophysical studies of the Rio Loa site have exposed highly anomalous ardennite and lead values, a key characteristic of gold mineralization within silicified resistive bodies. The studies have also produced initial findings which are similar to those seen at contiguous mines, such as Salares Norte (operated by Gold Fields), which has over five million ounces in estimated gold deposits.

The potential economics for the site look particularly promising when taking the unit costs at the neighboring Salares Norte mine into account. Gold Fields has estimated that its production AISC (all-in sustainable costs) will approximate $552 per ounce and have forecast a 2.3-year payback period for its initial investment, assuming a $1,300 per ounce gold price.

Coya Project

The Coya site is located within close proximity to one of the richest and largest epithermal gold and silver districts in Chile and is in close proximity to active mining sites, specifically the La Coipa mine owned by Kinross. A study carried out in 2017-2018 on the Coya site of 796 rock chip samples found favorable gold and silver values, in some cases ranking as high as 764 grams/tonne of gold and 719 grams/tonne of silver – values which are near certain indicators of potential gold and silver deposits. The La Coipa mine (Kinross) has produced over 6.9 million ounces of gold to date.

On August 11, 2020, GoldHaven Resources acquired five potential gold projects in the Maricunga Gold Belt of Northern Chile. The Maricunga hosts discoveries within the last 10 years of over 100 million ounces of gold and over 450 million ounces of silver. These newly acquired properties are in close proximity to seven other mines, which possess an estimated aggregate of 81 million ounces of gold in total reserves.

GoldHaven’s five new projects cover a total area of approximately 22,600 hectares, or 226 square kilometers, located in the northern portion of the Maricunga Belt in proximity to the 5 million-ounce gold equivalent Salares Norte project owned by Gold Fields. Gold Fields announced in April 2020 its intention to proceed with the development of Salares Norte at a cost of $860 million, with a $138 million expenditure budgeted for 2020.

The Maricunga Belt extends approximately 150 kilometers north-south and 30 kilometers east-west, straddling the border between Chile and Argentina. This region hosts known mineral resources of more than 100 million ounces of gold, 450 million ounces of silver and 1.3 billion pounds of copper.

The Maricunga project’s opportunity came about as a result of a $150 million initiative launched by the Chilean Economic Development Agency (“CORFO”), with the objective of encouraging exploration and mining prosperity in Chile and strengthening Chile’s position as a world leader in the sector.

As part of CORFO’s program, a total of $15.3 million was given to private equity fund IMT Exploration to evaluate 403 projects, beginning in 2011. This led to a generative program carried out from 2016 to 2019, resulting in 126 potential epithermal targets from which 57 field evaluations were made. Due diligence work followed on 19 of these. Work programs were then conducted, including geological mapping, rock and soil sampling and TerraSpec (PIMA) analyses on geochemical grids for alteration mapping, and, as a result, the five high-priority Maricunga projects were identified. No drilling has been carried out on any of the Maricunga projects.

Securing Financing for Upcoming Operations

In conjunction with its announcement regarding its acquisition of five Chilean mining interests, GoldHaven Resources also detailed plans for a non-brokered private placement of 11.5 million units at a price of $0.35 per unit, for gross proceeds of $4,025,000. Each unit will consist of one share of the company and one warrant, the latter of which can be exercised to acquire an additional share of the company for a period of 18 months from the date of issuance at a price of $0.50 per share. Net proceeds from the offering are intended to be used to fund general expenses, as well as exploration and drilling of its mineral properties.

Gold Prices Hit Record High in 2020

Gold prices have been on a remarkable run in 2020, breaking above $2,000 per ounce for the first time on record. Having begun the year at $1,515 per ounce, the precious metal has seen a huge surge on the back of widespread economic uncertainty stemming from governments’ worldwide propensity to expand the money supply, from the reduction of the value of the U.S. dollar as expressed by the decrease in the U.S. dollar index, and from the very real economic effects of the COVID-19 pandemic.

Global central banks have carried out 144 interest rate cuts thus far in 2020, reducing rates by a cumulative 5,035 basis points (http://nnw.fm/jzZt0). Meanwhile, the IMF has estimated that global governments have introduced fiscal support measures amounting to over $9 trillion since the start of the pandemic (http://nnw.fm/Or9rI). The resulting weakness in the U.S. dollar and eventual inflationary pressures stemming from these measures has prompted a number of investment banks to boost their near-term outlooks for gold prices, with Bank of America raising its 18-month gold price target to $3,000 per ounce (http://nnw.fm/PQJtc).

Leadership Team

David Smith, President, CEO and Director, has been immersed in the mining industry for the last eight years, working in corporate development and finance. Prior to GoldHaven Resources, Smith cofounded a multifaceted real estate development and sales company, which has now been in operation for over 35 years. He also cofounded two successful environment-focused companies listed on the Toronto Stock Exchange. Both companies were sold independently and returned a significant profit for shareholders.

Darryl Jones, Chief Financial Officer, is a finance executive and CPA with over 30 years of public company and project buildout experience. Most recently, Jones served as the CFO of Lupaka Gold Corp., retiring in June 2018. Prior to that, Jones serves as CFO of Corriente Resources, which was sold to CRCC-Tongguan in May 2010 for C$680 million.

Patrick Burns, VP Exploration and Director, is a Canadian geologist with over 40 years of experience throughout the Caribbean and Central and South America. He played a direct role in the discovery of the Escondida porphyry copper deposit in Chile and has been involved in publicly traded mining companies, predominantly in Chile, for 35 years.

Marla Ritchie, Corporate Secretary, brings over 25 years of experience in public markets to the GoldHaven team. Throughout this time, she has worked as an administrator and corporate secretary specializing in resource-based exploration companies. Currently, Ritchie is the corporate secretary for several companies, including International Tower Hill Mines Ltd. and Trevali Mining Corp.

Gordon Ellis, Director; has over 50 years’ experience in mining and resource development. A professional engineer and entrepreneur, he has held multiple senior management and director roles with public mining companies, as well as a multi-billion-dollar ETF fund. Ellis holds an MBA in international finance and a Chartered Directors designation.

Scott Dunbar, Director is a professor and head of multiple departments at the University of British Columbia, including mineral extraction and mining innovation, as well as mining engineering. He has been involved in projects around the world in regard to mining exploration, geotechnical engineering and mine design. Dunbar received his PhD in geophysics and civil engineering from Stanford University.

GoldHaven Resources Corp. (OTCQB: GHVNF), closed Friday’s trading session at $0.6813, up 0.457092%, on 99,390 volume with 51 trades. The average volume for the last 3 months is 93,640 and the stock's 52-week low/high is $0.109999999/$0.800000011.

Recent News

Creatd Inc. (NASDAQ: CRTD)

The QualityStocks Daily Newsletter would like to spotlight Creatd Inc. (NASDAQ: CRTD).

Creatd (NASDAQ: CRTD), a proprietary technology platform for creators of all types, has unveiled two new creator challenges for its Vocal platform subscribers. The two challenges — Mystery of Bitcoin Challenge for all subscribers and  both freemium and premium Vocal+ paid subscribers and Hometown Feature challenge for Vocal+ subscribers — include cash prizes for the winners. To view the full press release, visit https://ibn.fm/JJ0sG

Creatd Inc. (NASDAQ: CRTD) develops technology-based solutions to solve digital problems. Through the combination of design, thought and data analysis, the company builds products that influence a worldwide audience.

Creatd’s flagship product is Vocal, a proprietary long-form digital publishing platform that provides storytelling tools and engaged communities for creators to get discovered and fund their creativity.

Vocal

Designed to develop and cost-effectively engage content creators, the Vocal platform enables its over 500,000 registered content creators to reach an engaged audience and monetize their content. In addition to providing relevant content, Vocal’s technology is centered on efficiency and scalability through its niche digital communities, as well as output through its data-driven distribution strategy.

Vocal partners with content creators and brands that recognize difficulties inherent in the digital advertising space and that can benefit from branded content marketing opportunities available on publishing platforms like Vocal.

All content available on Vocal is created within the platform’s custom editor and published on one of Vocal’s embedded genre-specific communities, spanning topics that range from food to wellness, beauty, technology and more.

In May 2019, Creatd launched Vocal+, its premium subscription membership program. Vocal+ members pay a membership fee for premium value-added features, including receiving increased earnings for their content, reduced platform processing fees for tips received, a Vocal+ badge on their creator page, access to new features on the Vocal Platform, and other rewards. Creators can sign up for free or upgrade to Vocal+, available for purchase on either an annual or monthly subscription basis.

Vocal for Brands

Vocal for Brands is an in-house creative studio that generates actionable data from bespoke native advertising campaigns. Vocal for Brands partners with direct-to-consumer (DTC) to create beautiful, campaign-optimized stories on Vocal that build brand affinity, trust and drive results.

Additionally, Creatd provides a Managed Services offering to business-to-business (B2B) and business-to-consumer (B2C) product and service brands which encompasses a full range of digital marketing and e-commerce solutions. Managed Services includes the setup and ongoing maintenance of clients’ websites, Amazon and Shopify storefronts and listings, social media pages, search engine marketing, and other various tools and sales channels utilized by e-commerce sellers for sales and growth optimization. In addition to partnering with Managed Services clients, the company offers a range of la carte services.

Growth Strategy

On September 11, 2020, Creatd Inc. officially changed its name from Jerrick Media Holdings Inc. and uplisted its stock to the Nasdaq Capital Market. The company also announced the pricing of its underwritten public offering of 1,725,000 units of securities at an offering price of $4.50 per unit.

This rebranding initiated Creatd’s go-forward growth strategy and its plans to expand its offerings and provide technology products and resources for creators to help transform their ideas into reality. The strategic plan is designed to greatly increase Creatd’s potential market value via a plethora of new revenue streams.

Creatd focuses on a community of creators that includes more than 2.5 billion users, for which it will offer democratized, transparent platforms for distribution, sentiment, resources and monetization. The company’s agile development process will rely on a combination of bleeding-edge technology that eliminates barriers and creates efficiencies. Superior design thinking and data analysis will allow Creatd to expand its digital footprint to a global community.

Creatd intends to partner with a community of technology collaborators and sophisticated investors who collaborate to provide technology solutions for creators, brands and their respective audiences. The company’s solutions, business processes, technology platforms and design theories will lend themselves to application opportunities on a global scale.

History & Management

Creatd was founded in 2012. Initially a private media company providing online content through a portfolio of brands, Creatd’s needs quickly outpaced its initial technology and product offering. In 2015, Creatd partnered with Thinkmill, a premiere, Australia-based product design and development group to create a content management system (CMS) for its brands; that system evolved into the company’s flagship product, Vocal.

Today, Creatd’s management team is an impressive group of abstract thinkers united by their passion to solve problems. Leading the team are founder and CEO Jeremy Frommer, and Justin Maury, Creatd’s president and head of product.

Frommer’s career includes two decades in the financial technology industry, working as a hedge fund and portfolio manager, as well as on the sell-side of the financial industry. Frommer started NextGen Trading, a software development company building proprietary equity trading platforms. NextGen was acquired by Carlin Financial Group of which Frommer became CEO. RBC Capital Markets Corporation eventually bought Carlin. At RBC, Frommer was managing director, head of the Global Prime Services group and a member of the RBC Global Equities Operating Committee.

Maury joined Creatd in 2013, bringing with him 10 years of experience in the creative industry. Since partnering with Frommer to establish Creatd, Maury led the company’s product development for more than four years. His passion for the creative arts and technology ultimately yielded the vision for Vocal. During Creatd’s early formative years, Maury was a driving force in creating the vision, design and architecture for the Vocal platform and managing the oversight of technology development.

Creatd Inc. (NASDAQ: CRTD), closed Friday’s trading session at $4.77, off by 6.1024%, on 515,787 volume with 2,416 trades. The average volume for the last 3 months is 107,680 and the stock's 52-week low/high is $2.0999999/$5.92999982.

Recent News

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0)

The QualityStocks Daily Newsletter would like to spotlight MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0).

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) is an agricultural biotech company focused on developing and commercializing natural biological solutions for high-value crops, including fruits and vegetables. The company uses novel compounds from the mustard plant to provide superior and safer alternatives to current synthetic chemicals used as pesticides, fungicides and nematicides. Management & advisors own 22% of the company’s 37 million shares outstanding.

Leveraging its innovative platform, MustGrow effectively extracts the natural defense mechanisms of the mustard seed for broad use in crop production and protection. The company uses components of mustard seed to provide high quality, organic pest control to growers facing challenges associated with soil-borne diseases and pests like nematodes. This company’s all-natural, effective, safe and easy-to-use solution is ideal for farmers looking to raise healthy crops without chemical pesticides amid growing concerns worldwide over the negative effects of chemical pesticide solutions.

MustGrow, which went public in 2019, was founded in Saskatoon, Canada, and is currently focused on disrupting the $65 billion global pesticide market with its 100% owned and patented mustard-derived technology. Canada produces 28% of the global mustard crop and is the world’s largest exporter, with a 57% market share.

TerraMG and Pipeline

The company’s technology extracts the mustard plant’s natural organic compounds, which, when combined with water, form Allyl isothiocyanate (AITC) and serve as a natural defense mechanism for the plant against pests and diseases. MustGrow’s mustard-derived technology acts as both a natural bio-pesticide and as a non-selective bio-herbicide.

There are currently more than 110 independent third-party trials that confirm the safety and efficacy of MustGrow’s solutions, potentially positioning the company as a leading provider of safe plant protection solutions in a market that is gradually eliminating the use of chemical compounds.

MustGrow’s primary product at the moment is the new liquid formulation TerraMG, which has the potential to compete against existing chemistries on both efficacy and price. Its initial target market is as a pre-plant soil bio-pesticide for use with higher-value crops such as fruits and vegetables. This liquid formulation is safe and easy to transport and has already demonstrated its efficacy against several pests and diseases.

In addition to its use as a pre-plant soil treatment, TerraMG has significant potential for multiple applications in several other markets, which is expected to aggressively expand the company’s IP portfolio. MustGrow has already confirmed or is in the process of testing multiple applications of TerraMG, including fruit and vegetable soil fumigation ($1.2 billion estimated global market), container fumigation ($2 billion estimated global market), tobacco nematode and disease fumigation ($4 billion estimated global loss), non-selective herbicide ($13 billion estimated global market), food-borne pathogens ($15 billion estimated global market) and more.

The company anticipates registration approval for the liquid formulation (TerraMG) as a pre-plant bio-pesticide for soil-borne diseases and pests from the EPA (United States) and PMRA (Canada) in 2021. The company already has EPA and PMRA approval for the product’s granular form.

Currently, MustGrow’s pipeline also includes:

  • TerraMG, a pre-plant soil bio-pesticide, for:
    • Fruit & Vegetable – currently in Phase 4
    • Turf & Ornamental – currently in Phase 4
    • Tobacco – currently in Phase 4
    • Potatoes – currently in Phase 4
    • Canola – targeting Clubroot Disease – currently in Phase 3: Advanced Development/Field Trials
    • Bananas – targeting Fusarium wilt TR4 – currently in Phase 1: Proof of Concept/Laboratory
    • Pulse Crops – targeting Aphanomyces – currently in Phase 1: Proof of Concept/Laboratory
  • Non-Selective Bio-Herbicide – targeting noxious or resistant weeds – currently in Phase 2: Early Development/Greenhouse
  • Storage Bio-Pesticide for Bulk Grain, Fresh Produce – targeting toxins, diseases and insects – currently in Phase 1: Proof of Concept/Laboratory
  • Storage Bio-Pesticide for Shipping Containers – targeting fungus, invasive pests and diseases – currently in Phase 1: Proof of Concept/Laboratory
  • Bio-Pesticide for Foodborne Pathogens – targeting E. coli, salmonella, Listeria, human pathogens, etc. – currently in Phase 1: Proof of Concept/Laboratory

Market Opportunity

The protection of crops with synthetic chemical pesticides represents a $65 billion-dollar global market that is expected to grow in the coming years as the global population grows and needs more food. This number doesn’t include bio-pesticide sales, which are projected to increase to $8.5 billion by 2025, with a CAGR of 14.7%. MustGrow, with its natural bio-pesticide, is targeting not only the bio-pesticide market, but also the global synthetic chemical market so as to help replace harmful synthetic pesticides and provide a natural biologic that has the efficacy of controlling pests and disease compared to synthetic chemicals in some instances.

Management Team

Corey Giasson is the President, CEO and Director of MustGrow. He is an entrepreneur focused on the agriculture, mining, real estate and oil/gas industries, primarily in the Canadian province of Saskatchewan. Giasson is co-founder and director of Legacy Capital Corp. This private equity company focuses on participating in management buyouts of strong, sustainable cash flowing businesses. He has an MBA and B.Sc. in Agriculture Economics from the University of Saskatchewan.

Colin Bletsky is COO and Director of MustGrow. He grew up in Eastern Saskatchewan on his family’s third-generation farm, growing canola, wheat and oats. The majority of his time is spent helping other organizations and farmers grow their businesses – locally and globally. Bletsky has a Bachelor of Science in Agriculture from the University of Saskatchewan and executive education from the London School of Business and INSEAD.

Todd Lahti is the company’s CFO. He has extensive experience evaluating and managing biotech, agricultural and oil/gas start-up companies by working directly on financing transactions, mergers and acquisitions, business development, corporate strategy, technology transfer and operations setup. Lahti is a Chartered Financial Analyst and a Chartered Professional Accountant.

Brad Munro is Chairman of MustGrow. He is the President and CEO of Bittercreek Capital Corp., a private investment and advisory firm. He has extensive corporate finance and investment experience in the natural gas and oil industries, among others. Munro has a Bachelor of Commerce from the University of Saskatchewan.

MustGrow Biologics Corp. (OTCQB: MGROF), closed Friday’s trading session at $1.4977, off by 5.805%, on 113,429 volume with 143 trades. The average volume for the last 3 months is 81,569 and the stock's 52-week low/high is $0.124499998/$1.87.

Recent News

Loop Insights Inc. (TSX.V: MTRX) (OTCQB: RACMF)

The QualityStocks Daily Newsletter would like to spotlight Loop Insights Inc. (TSX.V: MTRX) (OTCQB: RACMF).

Loop Insights (TSX.V: MTRX) (OTCQB: RACMF) announced that it will be providing its complete venue management for the upcoming Paiute Las Vegas Championship. Loop was selected by bdG Sports, a representation, event management, and public relations firm, which is organizing the event. The Paiute Las Vegas Championship is slated for April 12–18, 2021, and will take place at the Las Vega Paiute Golf Resort. The tournament is part of the Korn Ferry Tour, which is the primary pathway for golfers seeking to earn their PGA Tour card. To view the full press release, visit http://ibn.fm/cPt5m

Loop Insights Inc. (TSX.V: MTRX) (OTCQB: RACMF) is an innovative technology company leveraging Internet of Things (IoT) technologies to deliver contactless solutions, including its venue management platform, personalized engagement services and AI-driven insights.

The company was founded on June 12, 2019, and is headquartered in Vancouver, Canada. Loop is currently offering its solutions to major players in the telecom, sports, casino gaming, hospitality, entertainment and retail industries across Canada, the United States, South America, the UK, Australia, Indonesia and Japan.

Scaled and Fully Managed Services

Loop Insights has integrated both its Fobi and SmarTap devices with its proprietary cloud to provide end-to-end services for the retail, travel, entertainment and hospitality industries.

Loop’s Automated Venue Management Platform

Loop’s venue management platform is a fully managed contactless check-in platform that securely aggregates venue and visitor information in order to generate real-time feedback to both venue hosts and consumers. Loop’s venue management platform can be applied to venue tracing for COVID-19 or used in traditional environments for applications in ticketing, retail and hospitality.

Loop’s COVID-19 Venue Tracing Solution

Loop Insights is committed to leveraging its solutions for COVID-19 management, allowing for easier tracing, testing and data collection.

Loop Insights has adapted its existing technology to create a venue management platform designed specifically for tracing the COVID-19 pandemic. The company’s complete end-to-end COVID-19 management platform provides a means for venues and event hosts to manage attendees and instantly trace and notify potential at-risk visitors.

Loop Insights has partnered with a number of medical testing companies including iSTOC and Empower Clinics to provide rapid testing options wherever its COVID-19 venue management system is deployed.

Loop Insights signed a referral and partnership agreement with Finland’s iSTOC Ltd. in November 2020, providing the company COVID-19 testing and integrated lab capabilities in Europe. The partnership allows Loop to provide FDA and HIPAA-compliant tracing and testing that can be deployed by any health care organization, NGO or government worldwide. “Our partnership with iSTOC positions us as a true global leader regarding complete COVID-19 management solutions,” Loop Insights CEO Rob Anson explained.

Through its partnership with Summit Services Inc., Loop Insights deployed the first-ever COVID-19 venue bubble solution in a live environment at the Gulf Coast Showcase in Fort Myers, Florida, and #VegasBubble in Las Vegas. The venue bubble was deployed to test, trace and notify over 500 NCAA players, coaches and staff that attended the tournament.

Loop’s Personalized Engagement Platform

Loop Insights’ personalized engagement platform leverages the power of the company’s technology to provide retail operators with an automated marketing platform focused on delivering the right marketing to the right customers to optimize retail engagement.

By leveraging the power of the Wallet pass functionality found on all Android and iOS devices, Loop establishes a direct line of communication with consumers, allowing merchants to provide an AI-personalized marketing experience designed to drive spending and encourage brand loyalty through rewards and other promotions.

Like the digital credit cards or boarding passes that use Wallet pass technology, Loop Insights’ engagement platform provides a seamless user experience without the need to download an additional application. Consumers receive automated promotions and discounts that can be personalized based on user data.

Loop’s Real-Time Insights Platform

By aggregating retail information about consumers and their preferences, Loop’s Insights platform takes the guesswork out of decision making for retailers. Loop’s Insights platform aggregates retail performance data, recording 100% of each transaction before delivering insights and analytics regarding macro and micro buying trends, consumer behavior and optimization opportunities.

As part of its Insights offering, Loop provides AI-based forecasting, modeling and inventory management services to retailers with the ability to integrate third-party data services such as foot traffic and weather.

Loop Insights Devices and Technologies

Loop Insights has developed a line of simple, yet powerful technologies designed to transform industries through the power of IoT technologies and artificial intelligence. The company offers fully automated plug-and-play platforms that can seamlessly integrate and enhance clients’ existing operational infrastructure. The company’s devices are designed to work together seamlessly on top of its enterprise-level cloud infrastructure, providing clients in the retail, entertainment and hospitality industries with the ability to easily optimize their operations.

Fobi

Fobi is an IoT device designed to seamlessly integrate into any existing point of sale or customer management infrastructure. It collects 100% of transactional data and then connects this data to other data points, enabling optimization through AI and data-driven insights.

Loop Insights’ cloud-based AI is designed to aggregate an organization’s data, optimizing the information so it is actionable and easy to use. The Fobi device is hardware agnostic and seamlessly connects with existing points of sale or customer relationship management infrastructure, physically or digitally.

By aggregating an organization’s entire dataset, Fobi is able to merge transactional and behavioral data with customer data to create 360-degree customer profiles, enabling highly-personalized, omnichannel marketing strategies across a number of platforms including email, SMS, paper receipts and the company’s proprietary Wallet pass technology. Loop’s data aggregation service is supported by Amazon Web Services, providing clients with the digital infrastructure and security necessary to protect their data.

SmarTap

SmarTap is a Near Field Communication (NFC) device that enables consumers to “tap” to check-in to locations using their smartphone’s NFC compatibility, enabling contactless customer engagement through the use of Wallet pass technology. By leveraging the functionality of the Wallet pass technology found on Android and iOS devices, Loop is able to drive engagement and provide personalized, data-driven insights without the need for an additional application.

Loop’s SmarTap device can connect to the Loop cloud via LTE or Wi-Fi, allowing retailers to securely transfer encrypted data from wherever their businesses operates.

Loop Cloud

The Loop Cloud brings together datapoints from its Fobi and SmarTap devices to create a unified database for the company and its clients. Instead of individual tills and stores generating their own unique datasets, Loop Insights aggregates data together from a number of sources, creating a complete picture of a client’s retail environment.

By hosting this database in the cloud, Loop Insights provides its clients with more accessible and actionable data that can be accessed from anywhere. Additionally, the Loop cloud allows for real-time monitoring, and its API can be directly integrated into existing PoS systems.

When paired with Loop’s Fobi and SmarTap devices, the Loop Cloud allows for businesses to transform their edge-based legacy systems into a unified database that can be accessed from anywhere.

Uklipz

Expected to launch in January 2021, Loop Insights’ latest product offering, Uklipz, is a next-generation platform that enables consumers to create verified video reviews that can be purchased, analyzed and leveraged by brands to drive engagement and sales.

The addition of Uklipz marks an important milestone for the company, because it further strengthens its product portfolio by providing a reliable solution in the massive but problematic consumer review industry, as Anson explained in a November 2020 news release (https://ibn.fm/YpNlR). He added that the company expects this platform to become a very valuable asset and a significant source of revenue in 2021.

Market Outlook

Loop Insights’ integrated technology solutions and its recent advances in providing end-to-end COVID-19 solutions position the company for significant growth opportunities in the expanding IoT market. According to MarketsandMarkets research, the global IoT sector is expected to reach $561 billion by 2022, up from $180.6 billion in 2017. This market growth can be attributed to an increase in cloud platform adoption and a reduction of costs (https://ibn.fm/1BIPB) which Loop is driving through its engagement and insights platforms.

According to Loop Insights’ August 2020 investor presentation, its innovative solutions open the door to multiple opportunities in additional sectors, including but not limited to:

  • Brick and mortar retail – an estimated value of $31,880 billion by 2023 (Mordor Research)
  • Sports and entertainment – an estimated value of $614.1 billion by 2022 (The Business Research Company)
  • Telecom partnerships – an estimated value of $3,435.2 billion by 2022 (The Business Research Company)
  • Casino gaming – an estimated value of $565.4 billion by 2022 (Research and Markets)
  • Cannabis – an estimated value of $66.3 billion by 2025 (Grandview Research Inc.)

Management Team

Rob Anson is the Chief Executive Officer and Chairman of Loop Insights. He has also served, since October 2017, as the Chief Executive Officer and Founder of Fobisuite Technologies Inc., a private British Columbia technology company. In a prior role, Anson was the Founder and Chief Executive Officer of One Team Media, a private Vancouver-based media company with digital and television production assets.

Abbey Abdiye is Chief Financial Officer of Loop Insights. He is a Chartered Professional Accountant (CPA) who has served as Chief Financial Officer for a range of public companies throughout his extensive career. Before obtaining his CPA, he received a Bachelor of Business Administration from Simon Fraser University and completed his Co-Op Education Certificate.

Gavin Lee is the company’s Chief Operating Officer. He has over 20 years of experience with global consumer products, with expertise in building top-performing sales teams, brand management, operational excellence and consumer insights. Lee has a strong business understanding and a background in improving salesforce effectiveness. His experience ranges from small entrepreneurial brands to multi-million-dollar global leaders in a variety of marketing segments.

Casey Matson-DeKay is Chief Technology Officer of Loop Insights. He previously held the same position at Fobisuite Technologies, from January 2017 until January 2018. Matson-DeKay has been a developer and information technology consultant for various enterprises. He has been involved with the core technologies utilized by Loop Insights for nearly a decade.

Loop Insights Inc. (RACMF), closed Friday’s trading session at $1.42, off by 1.6614%, on 73,450 volume with 119 trades. The average volume for the last 3 months is 72,523 and the stock's 52-week low/high is $0.000000999/$2.33990001.

Recent News

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed on its previously announced registered direct offering; the company also announced that it has completed definitive agreements with a number of institutional and accredited investors for a registered direct offering. To view both full press releases, visit https://ibn.fm/sqnsk and https://ibn.fm/W4KOJ

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Friday’s trading session at $1.36, off by 0.729927%, on 8,724,813 volume with 22,470 trades. The average volume for the last 3 months is 1,821,148 and the stock's 52-week low/high is $0.629999995/$5.30000019.

Recent News

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF)

The QualityStocks Daily Newsletter would like to spotlight Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF).

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) was featured today in a publication from PsychedelicNewsWire, examining how if you watch a lot of combat sports, you probably know that fighters take a risk every time they step into the ring. This is because fighters know, whether they’re in the UFC Octagon or a typical boxing ring, they’re going to get hit in the head. It doesn’t matter what causes the hit —an elbow, knee, foot or fist — the brain still suffers trauma.

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF), headquartered in Pemberton, British Columbia, is a plant-based extraction company with a new vertical in functional mushrooms. The firm is positioned to be the dominant extraction company and a leader in the rapid development and commercialization of functional and medicinal psychedelic products.

The Company’s business model consists of three verticals: in-house brands; toll processing, offering contract cannabis and hemp processing to Canadian Licensed Producers and international partners to sell under their own brands; and white labelling, supplying products, including edibles and custom formulated oils, in consumer-ready packaging for companies licensed to sell cannabis oil extracts and for CPG brands seeking licensed cannabis manufacturing partners.

Market Position

The psychedelic and functional mushroom industries are among the fastest growing in North America. As the industry transitions from dry biomass to extracts, many companies are unprepared for this new opportunity. The global medicinal mushroom market is expected to grow by $13.88 billion annually by 2024.

When assessing investment strategy, market analysts suggest that psychedelics are more comparable to biotech than to cannabis. Unlike traditional biotech, however, psychedelics can claim years of human consumption. Because their efficacy and safety are already well understood, the hurdles for development are likely to be lower. As known molecules, psychedelics won’t spend as much time in discovery and pre-clinical development.

Current research is finding psychedelic benefits including anti-tumor, anti-viral, detoxification, immune function, and mental wellness. As such, psychedelic compounds are now being examined by leading medical research and academic institutions for treatment of depression, PTSD, anxiety, bi-polar disorder, obesity, narcolepsy, OCD, Alzheimer’s, ADHD and drug and alcohol dependence. In 2020, the FDA granted breakthrough therapy status to psychedelics for treatment-resistant depression, with approvals anticipated in 2021.

Pure Extracts is well positioned to partner with organizations planning to develop both functional and psychedelic products. A dealer’s license with Health Canada will enable buying, selling and producing of psychedelics in an EU-GMP-compliant environment. The Company’s 10,000 square foot facility is designed for EU-GMP certification, which allows for international sales. The Company has signed NDAs to explore joint development endeavors for Q4 2020 product launches, as well as an advisory agreement with Dr. Alexander MacGregor, founder of Transpharm Canada Inc. (“TCI”), the parent company of Toronto Institute of Pharmaceutical Technology, whose facility is a fully compliant Health Canada licensed Good Manufacturing Practice (“GMP”) manufacturing and testing facility and is a full-service clinical development business that provides clinical trial services to biotechnology companies.

Research on Psychedelics

Naturally occurring psychedelics, like psilocybin mushrooms, peyote and ayahuasca, have been used by humans for centuries. First seen as potentially medicinal in 1938 by a chemist at Sandoz Pharmaceuticals (now Novartis), the desired stimulant effect was unsuccessful and therefore the drug was shelved. Twenty years later, in 1958, Sandoz began selling lysergic acid diethylamide (LSD) to treat mental disorders. From 1950 to 1965, over a thousand scientific papers on these compounds were published. During the 1960s, however, psychedelics made their way out of the lab and onto the street. The war on drugs followed, and psychedelic research essentially ended.

Research continued slowly on the fringes. The Multidisciplinary Association for Psychedelic Studies was formed in 1986 with the goal of becoming a leading non-profit psychedelic pharmaceutical company. Still being researched, psychedelics’ primary and most common mechanism of action is agonism of serotonin receptors in the brain, which promotes serotonin production in order to regulate mood.

Growing societal awareness and acceptance of mental illness as a legitimate disease due, in part, to its increasingly prevalence have been a catalyst for a new search for innovative treatments. As such, interest in psychedelic medicines has been revived in recent years.

Extract Segment Leader with Cannabis

Canada’s cannabis industry is dominated by dried flower products. Extract products are estimated to represent only 13% of the market share. With no dominant brands in the cannabis sector, Pure Extracts is the development leader in this segment, which is estimated by Deloitte to be worth $2.7 billion annually. Pure Pulls, the company’s private label brand, is nationally recognized through compliant event sponsorship and ongoing product engagement.

Management Team

Pure Extracts is led by a team of dedicated professionals leveraging extensive industry knowledge.

Ben Nikolaevsky, the company’s CEO, has more than a decade of experience in corporate leadership roles across the natural products, agriculture and cannabis sectors. Nikolaevsky has served as CEO at Natura Naturals Inc. and Blue Goose Capital Corp., as well as market vice president at CIBC and chief credit officer & capital markets manager at IBM Global Financing Canada.

Doug Benville founded Pure Extracts and serves as the company’s COO. He is highly proficient in cannabis cultivation, system operations and oil extraction.

Alexander Logie, Pure Extracts’ vice president of business development, has over 30 years of experience in the financial services sector, having most recently served as interim CFO, COO and senior vice president of business development at Natura Naturals Inc., a licensed cannabis producer acquired at the start of 2019.

Andy Gauvin is vice president of sales for Pure Extracts. Gauvin is an accomplished senior sales leader with over 30 years of experience in the cannabis space. Gauvin also brings extensive knowledge of the complex federal and provincial regulatory environment to the Pure Extracts team.

Pure Extracts Technologies Corp. (CSE: PULL), closed Friday’s trading session at $0.56087, off by 3.2983%, on 35,447 volume with 29 trades. The average volume for the last 3 months is 28,260 and the stock's 52-week low/high is $0.455659985/$1.00.

Recent News

PowerBand Solutions Inc. (TSXV: PBX) (OTCQB: PWWBF) (Frankfurt: 1ZVA)

The QualityStocks Daily Newsletter would like to spotlight PowerBand Solutions Inc. (TSXV: PBX) (OTCQB: PWWBF) (Frankfurt: 1ZVA).

PowerBand Solutions Inc. (TSXV:PBX)(OTCQB:PWWBF) (Frankfurt: 1ZVA) ("PowerBand", or the "Company") is pleased to announce its intention to complete a non-brokered private placement financing for gross proceeds of up to $5.3 million (the "Private Placement"). The Company intends to the use the net proceeds from the Private Placement to support its continual development, growth, market expansion and for general working capital purposes. Up to 18,275,862 units will be placed (the "Units"), at a price of $0.29 per Unit, with the objective of raising up to $5,300,000. Each Unit will consist of one common share and one common share purchase warrant (the "Warrants") of the Company. Each Warrant will entitle the holder to purchase one common share of the Company at an exercise price of $0.49 for a period of 24 months from their date of issuance.

PowerBand Solutions Inc. (TSXV: PBX) (OTCQB: PWWBF) (Frankfurt: 1ZVA) is revolutionizing the world’s automotive industry with a cloud-based platform that makes buying, selling, leasing and trading cars and trucks as easy as purchasing a product on Amazon or ordering an Uber from a smart phone. PowerBand offers auction and finance portal software tools that increases sales, efficiencies and profitability to its customers and dealers. It provides a transparent, simple, buy-sell online-auction and inventory-management system.

A Better Way to Connect and Acquire Vehicles

PowerBand’s mission is to create an online, consumer-directed marketplace that streamlines the interactions among all participants in the automotive industry. It transforms today’s antiquated business model with speed, transparency, access to information and ease of use for consumers and dealers.

Consumers can easily connect with new sources to buy vehicles, network with motivated buyers and sellers, maximize their trade-in values, improve their customer experience. PowerBand’s standardized system and transaction process also increase efficiencies and benefits with hands-on, process-driven, in-store training and support.

Through internal development, acquisitions, joint ventures and strategic partnerships, PowerBand is developing solutions for consumers, dealers, manufacturers, commercial customers and lenders that are poised to transform the trillion-dollar U.S. automotive industry.

The PowerBand Auto Platform

PowerBand’s transaction platform was developed by a team of experienced automotive, technology and finance experts, and has been refined through years of operational experience. Built on the core belief that the consumer prefers to primarily conduct automotive transactions online and avoid interactions with unnecessary middlemen, PowerBand’s product solutions include:

  • Leasing: PowerBand is currently licensed in 33 U.S. states via a majority interest in MUSA Auto Finance LLC, an advanced online leasing technology platform that has transformed the new and used vehicle leasing industry. MUSA is the only approved, non-captive lease partner for Tesla in the U.S., and the platform can approve leases in a matter of seconds.
  • Inventory and Financing: A partnership with RouteOne LLC, a leading financial platform founded in 2002 by Ally Financial, Ford Motor Credit Co., TD Auto Finance and Toyota Financial Services, allows access to a network of more than 18,000 dealerships and 1,400 financing sources.
  • Auction Platform: PowerBand and its joint-venture partner, D2D Auto Auctions, are developing a direct consumer-to-dealer and a consumer-to-consumer automotive portal, which will provide an innovative alternative to physical dealership and auction locations.
  • LiveNet Auction: An online platform portal that allows dealers to create instant live vehicle auctions to a vast network of the industry’s top used vehicle buyers.
  • MarketPlace Auction: An online listing auction site for buying and selling automotive inventory – ideal for dealers, fleet, OEM and rental companies.
  • Used Vehicle Inspections: An LOI agreement with TÜV NORD Mobility Inc., a German-based global leader in vehicle inspections operating in more than 70 countries, will provide the most comprehensive, certified vehicle inspection reports available in North America. Appointments booked within the platform can be performed nearly anywhere.
  • Product Development: PowerBand’s comprehensive consumer solution, Driveaway, will be a fully transactional consumer marketplace where dealers and consumers can buy, sell, trade-in and finance vehicles, often in seconds, from the comfort of their home.

Automotive’s Growing Markets

The automotive dealership and commercial fleet vehicle auction industry is a $100-billion sector with more than 40 million used vehicles transacted in the U.S. each year. Of those, ten million are sold through auctions. From 2013 to 2017, the growth of online-only auctions far outpaced physical auctions, growing at a 33% compound annual growth rate compared to 2% CAGR at physical auctions.

Automotive leasing is another large, growing and fragmented market, generating approximately $120-billion in annual revenue. As a percentage of vehicle sales, leasing reached 30% in 2018, up from 21% in 2012, and is seen as a substantial opportunity for PowerBand and MUSA Auto Finance. Using proprietary technology and by focusing on high-quality, credit-worthy customers, MUSA grew its automotive lease originations to $182 million.

Disrupting Auto Leasing with MUSA

Legacy solutions are complicated, expensive and slow at processing leases. MUSA’s first-of-its-kind technology platform eliminates third-party decisions and the human capital required in the underwriting process. MUSA’s platform navigates the entire customer experience – underwriting, funding and the delivery process – within minutes. Leases can be approved in seconds.

PowerBand’s acquisition of MUSA brings together two leading-edge companies with the vision to become a one-stop platform for the entire vehicle purchase lifecycle.

Experienced Leadership

PowerBand is led by a collection of automotive veterans with a passion to collectively and positively impact the industry.

  • Kelly Jennings, president and CEO, is the founder of PowerBand Solutions and a franchise dealer owner/operator with more than 27 years of automotive experience. Jennings received General Motor’s Triple Crown Award, Ford Motor Company President’s Award and Honda Canada’s Excellence Award.
  • Darrin Swenson, COO of PowerBand and D2D Auto Auctions/Hunt Automotive Group, has more than 25 years of automotive/auction experience.
  • Jeff Morgan, CEO MUSA, holds over 25 years of experience in the auto finance sector.

PowerBand Solutions Inc. (OTCQB: PWWBF), closed Friday’s trading session at $0.51, off by 2.7831%, on 137,562 volume with 62 trades. The average volume for the last 3 months is 192,690 and the stock's 52-week low/high is $0.058187998/$0.56550002.

Recent News

VistaGen Therapeutics Inc. (NASDAQ: VTGN)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics Inc. (NASDAQ: VTGN).

VistaGen Therapeutics Inc. (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (CNS) disorders.

The company is headquartered in South San Francisco, California, the “Birthplace of Biotechnology,” among the largest cluster of biotechnology companies in the world.

New Generation Medications

VistaGen currently has three innovative CNS drug candidates in its pipeline: PH94B, PH10 and AV-101. With a differentiated mechanism of action and an exceptional safety profile in all clinical studies to date, each of VistaGen’s three drug candidates offers significant commercialization potential in multiple large CNS markets.

PH94B

Fast-acting (10-15 minutes), non-systemic and non-sedating in Phase 2 clinical studies, PH94B is a first-in-class neuroactive nasal spray that, administered in microgram doses, binds to chemosensory receptors in the nasal passage that trigger neural circuits responsible for suppressing fear and anxiety caused by stressful social or performance situations.

PH94B is currently being developed as an acute treatment of anxiety in adults with Social Anxiety Disorder (SAD). In December 2019, PH94B became the first drug candidate to be granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for development of a treatment for SAD, positioning it to potentially become the first FDA-approved fast-acting acute treatment for adults with the anxiety disorder, if planned Phase 3 studies are successful.

A successful Phase 2 program has been completed, and, after achieving consensus with the FDA in mid-2020 that the design of its Phase 3 studies of PH94B in SAD may mirror the design of the highly statistically significant (p=0.002) Phase 2 public speaking study of PH94B in SAD, the company’s preparations for pivotal Phase 3 clinical development of PH94B are underway.

To support Phase 3 development and commercialization of PH94B for anxiety disorders in large anxiety disorder markets in Asia, VistaGen recently entered into a strategic licensing and collaboration agreement with EverInsight Therapeutics, a company formed and currently funded by a large global venture capital firm, CBC Group. The company received a $5 million non-dilutive upfront license payment from EverInsight in August 2020. If Phase 3 development is successful, VistaGen is eligible to receive additional development and commercial milestone payments of up to $172 million, plus tiered royalties on sales of PH94B in Greater China, South Korea and Southeast Asia. VistaGen retains exclusive rights to develop and commercialize PH94B in all other markets.

VistaGen is also assessing potential Phase 2A clinical development opportunities to evaluate PH94B in a range of other anxiety disorders, including:

  • Adjustment Disorder with Anxiety
  • Generalized Anxiety Disorder
  • Postpartum Anxiety
  • Perioperative Anxiety
  • Panic Disorder
  • PTSD

PH10

PH10 is an investigational fast-acting synthetic neuroactive nasal spray with therapeutic potential in a wide range of neuropsychiatric indications involving depression and suicidal ideation. VistaGen is initially developing PH10 as a potential fast-acting, non-sedating, non-addictive new generation treatment of major depressive disorder (MDD).

Upon self-administration, a microgram-level dose of PH10 sprayed into the nose binds to nasal chemosensory receptors that, in turn, activate neural circuits in the brain that lead to rapid-onset antidepressant effects, without side effects, systemic exposure or safety concerns that may be caused by FDA-approved drug treatments for MDD, including oral antidepressants and intranasal esketamine.

In a published exploratory Phase 2A MDD study, PH10 demonstrated rapid-onset and sustained antidepressant effects without the serious psychological side effects and safety concerns of ketamine-based therapy.

Following successfully completed Phase 2A development of PH10 for MDD, the company is currently preparing for a Phase 2B program in MDD.

VistaGen is also assessing the potential for Phase 2A clinical development of PH10 in a range of other depression-related indications, including:

  • Postpartum Depression
  • Treatment-resistant Depression
  • Suicidal Ideation

AV-101

Part of a class of new generation investigational medicine in neurology and neuropsychiatry known as N-methyl-D-aspartate receptor (NMDAR) modulators, AV-101 is an oral prodrug of 7-chloro-kynurenic acid (7-Cl-KYNA), a potent and selective NMDAR glycine site antagonist. This drug candidate has the potential to serve as an innovative treatment for MDD and multiple neurological indications where current therapies are unsatisfactory.

VistaGen is currently evaluating AV-101, in combination with FDA-approved probenecid, in a range of neuropsychiatric and neurological indications, with both MDD and Neuropathic Pain already granted Fast Track designation by the FDA. The company is assessing the combination for a potential Phase 1B study to support a potential Phase 2A program in one or more of the following indications:

  • Major Depressive Disorder
  • Neuropathic Pain
  • Levodopa-induced dyskinesia associated with Parkinson’s disease therapy
  • Epilepsy
  • Suicidal Ideation

CNS Therapeutics Market Outlook

The global CNS therapeutics market is estimated to reach $130 billion by 2025. The market was valued at approximately $82.3 billion in 2017 and is anticipated to grow at a healthy CAGR of more than 5.93% from 2018 to 2025. Even before the onset of the anxiety- and depression-provoking stressors from the COVID-19 pandemic, this growth was expected to be driven by a rise in mental illnesses and increased awareness of psychiatric disorders (https://nnw.fm/K2m0s) – all likely to be amplified by the diverse impacts of the pandemic.

The two most common mental health conditions – anxiety and depression – cost the global economy an estimated $1 trillion each year. The impact of these conditions is particularly devastating among the young. Industry data suggest that approximately 20% of the world’s children and teens are affected by mental health conditions, and suicide is the leading cause of death among 15- to 29-year-olds (https://nnw.fm/oftNb).

VistaGen’s mission is to help address the unmet needs of patients suffering from CNS disorders whose current treatments are either inadequate or generate debilitating side effects and serious safety concerns, including risk of abuse and death.

“Now more than ever, the new generation anti-anxiety and antidepressant medications we are developing at VistaGen – PH94B, PH10 and AV-101 – are relevant, necessary and demand the highly-focused and passionate efforts of our team and partners, with the support of our stockholders, to advance them to patients whose lives are disrupted by anxiety and depression disorders,” VistaGen CEO and Director Shawn K. Singh said in his closing remarks at the company’s 2020 Annual Meeting of stockholders.

Management Team

Shawn K. Singh, J.D. is the Chief Executive Officer and a Director of VistaGen. He has served on the company’s board of directors since 2000. He has nearly 30 years of experience serving in numerous senior management roles across multiple industries, including private and public biotechnology, pharmaceuticals, medical devices, venture capital, contract research and development, and law. Singh has a B.A. with honors from the University of California – Berkley. He has a J.D. degree from the University of Maryland Carey School of Law. He is also a member of the State Bar of California.

H. Ralph Snodgrass, Ph.D., is the Founder, Chief Scientific Officer and Director of the company. Snodgrass has more than 20 years of experience in the biotechnology field as a senior manager. He is recognized as an expert in stem cell biology, with over 28 years of experience using stem cells as biological research tools to promote development and drug discovery. He received a Ph.D. in immunology from the University of Pennsylvania. Snodgrass has published over 50 scientific papers with more than 17 patents and a number of patent applications.

Mark A. Smith, M.D., Ph.D., is VistaGen’s Chief Medical Officer He has over 20 years of pharmaceutical industry experience, primarily with CNS drug development. Smith has been a successful leader in the discovery and development of approximately 20 investigational new drugs. He has been a part of numerous CNS-related clinical trials. Smith received a bachelor’s and Master of Science from Yale University and a Doctor of Medicine and Doctor of Philosophy in Physiology and Pharmacology from the University of California – San Diego. He completed his residency in the psychiatry department at Duke University Medical Center.

Jerrold D. Dotson, CPA, is the Vice President, Chief Financial Officer and Secretary of VistaGen. He has over 25 years of experience in senior management positions in finance and administration at both public and private companies. Dotson is a licensed CPA in California and received his B.S. degree (Cum Laude) in business administration with a concentration in accounting from Abilene Christian College.

Mark A. McPartland is the company’s Vice President of Corporate Development and Investor Relations. He has over 20 years of experience in senior management roles in corporate development and investor relations at both public and private companies. McPartland received his Bachelor’s in business administration and marketing from Coastal Carolina University.

VistaGen Therapeutics Inc. (NASDAQ: VTGN), closed Friday’s trading session at $2.21, up 6.7633%, on 1,647,398 volume with 3,853 trades. The average volume for the last 3 months is 2,045,364 and the stock's 52-week low/high is $0.300000011/$2.63969993.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.